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OPl
Trial Designs to Assess Biomarkers in Clinical Practice
Lucinda Billinghaml, Richard Stephens2, Michael Snee3, David Ferry4
l " International Lung Cancer Conference
1 Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK; 2 Medical
Research Council Clinical Trials Unit, London, UK; 3 Cookridge Hospital, Leeds, UK; 4 New Cross
Hospital, Wolverhampton, UK
Introduction: Biomarkers that are predictive of a patient's response to treatment are of great interest,
as they can be used to target treatment and maximise efficiency of health care resources. For example,
evidence exists that ERCCl expression levels may be predictive of response to platinum treatment in
non-small cell lung cancer.
Purpose: Once potential biomarkers have been discovered, formal evaluation in a randomised trial is
required to provide reliable evidence of patient benefit when used in clinical practice. Various trial
designs for this purpose have been proposed (Simon R 2008; Sargent D et al 2005) and choosing the
most appropriate for the specific situation is crucial. This OP will illustrate, using lung cancer examples,
the advantages and disadvantages of different designs.
Methods: Four designs are considered. The marker-based strategy design randomises patients to a
marker-based treatment strategy or not. The targeted trial design randomises only those patients with
positive markers to receive either experimental or control treatment. The stratified trial design and the
marker by treatment interaction design stratify patients prior to randomisation by the marker and then
randomise to experimental or control but the aim of the former is to compare treatments within each
strata whilst the latter tests for a treatment-marker interaction.
Results and Conclusions: There will be an escalation in randomised trials designed to assess the value
of biomarkers. Trialists need to be aware of the different designs and their advantages and
disadvantages to ensure the research question is answered in the most effective and efficient way.
OP2
VEGF-A loop in stage I NSCLCcells predicts a good outcome
J. Agorretal,2, MJ. Pajaresl,2, A. VesinlO, M. Larrayozl,2, T. Ezpondal,2, 1. Zudairel,3, R. Piol,4, JJ.
Zulueta5, M.D. Lozano6, 1. Gil-BalO7, E. Brambilla8, e. Brambilla9, J.F. TimsitlO, J.e. Soriall, EU-ELC
Consortium and L.M. Montuengal,2
lOncology Division, Center for Applied Medical Research. Departments of 5Neumology, 6Pathology, and
70ncology, Clfnica Universitaria de Navarra and Departments of 2Histology and Pathology, 3Genetics
and 4Biochemistry, Schools of Medicineand Sciences, University of Navarra; Pamplona, Spain.
Departments of 8Pathology, 9Respiratory Disease and 10Epidemioiogy INSERM U823 CHU A Michallon,
Grenoble, France. llDepartment of Medicine, Institute Gustave Roussy, Villejuif, France.
Vascular endothelial growth factor A (VEGF-A) mediates its effects through the VEGF receptors 1 and 2
(VEGF-Rl, VEGF-R2). VEGF-A regulates angiogenesis in healthy and tumour tissues. An anti-VEGF
therapy has been accepted for treatment in advanced non-small cell lung cancer (NSCLC) in Europe and
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USA. However, the prognostic value of VEGF-A in early lung cancer is still controversial. The aim of the
present study was to determine the prognostic value of VEGF-A, VEGF-R1 and VEGF-R2, in a series of
early stage NSCLC and its possible correlation with microvessel density (MVD). The present study is
part of the EUELC (European Early lung cancer detection group) project. Tumour samples were
collected from 303 stage I-IlIA patients and separated into two groups: progressive disease (PD;
recurrence or metastasis) and disease free (DF). Immunohistochemical procedure was used to detect
VEGF-A, VEGFR1, VEGFR2 and CD-34 (indirect measure of MVD) and results were analyzed by
semiquantitative methods.
Five different controls, including siRNA inhibition and analysis of human xenotransplanted tissue in nude
mice, were performed to confirm the specificity of our immunohistochemical results. A "VEGF-A
signalling score" was calculated as the sum of VEGF-A, VEGF-R1 and VEGF-R2 scores.
Multivariate analysis using the Fine & Gray adaptation of Cox proportional hazard model was
performed. Interestingly, there was no association between VEGF expression in tumour cells and MVD
(p=0.192). Multivariate analysis revealed VEGF signalling score as an independent prognostic factor for
progression-free survival (HR=0.58 (0.38 - 0.87), p=0.0088), especially in the case of stage I patients
(HR=0.52 [0.34-0.79]; p=0.0019). These results suggest that tumour VEGF-A expression is not related
to angiogenesis in early NSCLC and that the "VEGF-A signalling score" is a good prognostic factor for
Stage I.
OP3
FHIT gene inactivation in lung cancer patients
Carla Verri1, Luca Roz1, Davide Conte1, Triantafillos Liloglou2, Anna Livio1, Aurelien Vesin3, Alessandra
Fabbri4, Francesca Andriani1, Luca Tavecchio5, Elisa Calabros, Diego Tosi6, Paolo Bossi6, John K
Field2, Elisabeth Brambilla3 and Gabriella Sozzi1 and the EUELC consortium.
1Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Experimental Oncology, Milano, Italy;
2Cancer Research Centre, The University of Liverpool, Roy Castle Lung Cancer Research Programme,
Liverpool, UK; 3 INSERM U823, Univ.J.Fourier, CHRU Grenoble H6pital Michallon, Department of
Pathology, Grenoble, France; 4Fondazione IRCCS Istituto Nazionale dei Tumori, Department of
Pathology, Milano, Italy; 5Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Thoracic
surgery, Milano, Italy; 6Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Oncology,
Milano, Italy.
Introdution: Fragile Histidine Triad (FHIT) is a tumor suppressor gene involved in the pathogenesis of
lung cancer.
Objective: The purpose of this study was to investigate the different types of molecular alterations
leading to the inactivation of FHIT gene function and to validate their use as biomarkers of risk for
progression of the disease in patients resected for early stage lung tumors belonging to a multicentric
European study (EUELC).
Method: We assessed the methylation status by nested-MSP in 232 tumor and
225 normal lung samples of which a subset of 187 patients had available normal/tumor DNA pairs. LOH
at the FHIT locus was analyzed in 202 informative cases by D3S1300 and D3S1234 microsatellite
markers. FHIT immunostaining was performed in 305 tumor samples.
Results and Conclusions: 36.7% of tumor and 32.7% of normal lung samples showed methylation of
the FHIT promoter whereas LOH was detected in 61.9% of the tumors. Extensive loss or reduced FHIT
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expression was found in 45.6% and in 74.7% of the tumor samples, respectively. A strong correlation
with complete loss of FHIT expression was present when methylation and LOH were analyzed together
(p=O.0064). Loss of FHIT protein expression was significantly higher in squamous cell carcinoma
histotype (p<O.OOOl) and in smokers (p=O.008). FHIT methylation in normal lung was associated with
an increased risk of progressive disease (OR=2.27, p=O.0415). Our results indicate that different
molecular mechanisms interplay to inactivate FHIT expression and support the proposition that FHIT
methylation in normal lung tissue could represent a prognostic marker for progressive disease.
OP4
Splice isoforms of VEGF-A and its receptors in NSCLC
M. Larrayozl,2, J. Agorretal,2, R. Piol,3, MJ. Pajaresl,2, T. Ezpondal,2, I. Zudairel,4, C.E. Garda
Franc05, EU-ELC Consortium, J.K. Field6 and L.M. Montuengal,2
lOncology Division, Center for Applied Medical Research. Departments of 2Histology and Pathology,
3Biochemistry and 4Genetics. Department of 5Thoracic Surgery, Clinlca Universitaria de Navarra,
Schools of Medicine and Sciences, University of Navarra; Pamplona, Spain. 6Roy Castle Lung Cancer
Research Programme, University of Liverpool CancerResearch Centre, Liverpool, UK.
Vascular endothelial growth factor (VEGF) is involved in angiogenesis and tumour growth. In humans,
there are 9 isoforms of VEGF-A produced by alternative splicing, the main of them being: VEGF121,
VEGF165 and VEGF189. VEGF regulates angiogenesis in healthy and tumour tissues by interacting with
VEGF receptor 1 (VEGF-Rl; Flt-l) and VEGF-R2 (KDR).
The objective of the present study was to analyze the expression of different VEGF-A isoforms and
receptors in samples of patients with early non small cell lung cancer (NSCLC), and their correlation
with the histological type and the postoperative relapse.
We optimized a quantitative PCR procedure to determine the expression of different VEGF-A isoforms
(VEGF121, VEGF165 and VEGF189) and receptors
(VEGFR-l and VEGFR-2) in 24 primary NSCLC patients from the EUELC project (stages lA-IlIA).
Patients were divided into two groups: progressive disease (PD) and disease free (DF).
The expression of VEGF-A (p=O.0759), VEGF-Rl (p=O.0705) and VEGF-R2
(p=O.0316) tended to be higher in adenocarcinomas than in squamous cell carcinomas. Statistical
differences were found when the two larger isoforms were analyzed separately [VEGF165 (p=O.0155)
and VEGF189 (p=O.0359)]. Total VEGF-A expression tended to be higher in DF than in PD patients
(p=O.0658). When expression of VEGF isoforms was analyzed, significantly higher levels of all isoforms
were found in DF patients
[VEGF121 (p=O.0219), VEGF165 (p=O.0219) and VEGF189 (p=O.0490)]. VEGF-R2 expression was also
higher in DF patients (p=O.045).
In conclusion, the mRNA expression of VEGF-A isoforms and VEGF-R2 seems to be associated with
disease-free survival.
OPS
Isolation of Tumour Initiating Cells from lung cancer
E17K mutation in AKTl gene in lung epidermoid carcinoma
Donatella Malangal,2, Carmela De Marcol,2, Nicla De Rosa3, Gaetano Rocco-l, Giuseppe Pirozzi4,
Giuseppe Vigliettol,2
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Dysregulation of PI3K pathway plays a role in the development of lung cancer as PTEN loss or AKT
activation represents an unfavourable prognostic indicator for lung cancer patients. We investigated the
gene encoding AKT1 in NSCLC, through direct sequencing, in 105 resected, clinically annotated non-
small cell lung cancer specimens. We detected a
G->A transition at nucleotide 49 (that results in E->K substitution at
residue 17) in two squamous cell carcinoma (2/36) but not in adenocarcinoma (0/53). The activity of
endogenous kinase carrying the E17K mutation immunoprecipitated from tumour tissue was
significantly higher compared with the Wild-type kinase immunoprecipitated from adjacent normal
tissue as determined both by in vitro kinase assay using a consensus peptide as substrate and by in
vivo analysis of the phosphorylation status of AKT1 itself (pT308, pS473) or of known downstream
substrates such as
GSK3 (pS9/S22) and p27 (T198). Immunostaining or immunoblot analysis indicated that enhanced
membrane localizationexhibited by endogenous
E17K-AKT1 may account for increased activity of mutant AKT1 in comparison with the Wild-type protein
from normal tissue. Subsequently, we investigated the effects exerted by E17K-AKT1 in a cellular model
of lung carcinoma. We found that cells transfected by E17K-AKT1 are more resistant to drug-induced
apoptosis in vitro and are more tumourigenic in vivo. In conclusion, our data provide evidence that
mutant E17K-AKT1 contribute to the development of a subset of squamous lung carcinomas (5.5%).
OP6
Use of plasma&#12289;blood cell DNA concentration and LDH level as Prognostic factor of
non-small cell lung cancer
Minglin Ho
Changhua Christian Hospital, No. 135 Nanhsiao Street, Changhua City, Taiwan, R.O.C.
Background: Patient with NSCLC have a poor outcome mainly due to difficult early diagnosis. Analysis
of circulating DNA in plasma, blood cell DNA and LDH as prognostic markers are promising noninvasive
diagnostic tools.
Methods: 32 informed patients with advanced NSCLC and 42 healthy controls were included in the
study. DNA concentration was determined in paired plasma and blood cell DNA concentraction and LDH
levels. Patient prognostic factor was analyzed relative to baseline DNA concentrations, and the
relationship between the outcome and the LDH levels and changes in DNA concentration were assessed
in patients that received treatment.
Results: Plasma DNAvalues were significantly increased in NSCLC patients.
Plasma DNA concentration in the NSCLC patients (median 5.33 nq/rnf) were significantly higher
(p=0.00000002) than that in the healthy control patients (median 1.39 nq/rnl) and the area under the
curve was 0.819 (95% CI 0.728-0.91) for healthy versus NSCLC that it can to make the differentiation
between healthy and NSCLC.Further more, combination of blood cell DNA concentraction and LDH level
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before treatment were significantly associated with overall survival (p=0.0003).There are strong
similarities between the three biomarkers and survival in NSCLC. No association was observed between
survival and clinicopathological parameters.
Conclusion: The plasma DNA concentraction was different between healthy and NSCLC patients. The
blood cell DNA concentraction and LDH level were for prognostic factor in the future and with
combination the blood cell DNA concentraction and LDH level before treatment was significantly
associated with overall survival.
OP7
Romol-derived ROS are indispensable for the proliferation of cancer cells and enhances
the invasive potential of tumour cells
Young Do Yaa1, Seung Baek Lee1, Seon Ho Park1, Jin Sil Chung1, Jung Jin Kim1, Kee-Ho Lee2
1 Graduate School of Medicine and Brain Korea 21 Program for Biomedical Science, Korea University
College of Medicine, Korea University, Seoul 136-705, Republic of Korea.
2Laboratory of Molecular Oncology, Korea Institute ofRadiological & Medical Sciences, 215-4
Gongneung-dong, Nowon-ku, Seoul, 139-706, Korea.
Low levels of endogenous reactive oxygen species (ROS) originating from NADPH oxidase have been
implicated in various signaling pathways induced by growth factors and mediated by cytokines.
However, the main source of ROS is known to be the mitochondria, and increased levels of ROS from
the mitochondria have been observedin many cancer cells. Thus far, the mechanism of ROS production
in cancer cell proliferation in the mitochondria is not well-understood. We recently identified a novel
protein, ROS modulator 1 (Romol), and reported that increased expression of Romo1 triggered ROS-
production in the mitochondria. The experiments conducted in the present study showed that Romo1-
derived ROS were indispensable for the proliferation of both normal and cancer cells. We also show
that Romo1 expression directly contribute to invasive activity of cancer cells and a higher level of
Romo1 expression was detected in 39 out of 79 tumor tissuess, compared with the corresponding
normal tissues.
Interestingly, Romo1 expression showed a strong negative correlation for 12-year survival in tumor
patients. The results of this study suggest that Romo1-induced ROS may play an important role in
redox signaling in cancer cells.
OPS
A proposal for the evaluation of Stereotactic Radiotherapy in early stage non-small cell
lung Cancer -The Christie Hospital Initiative
Corinne Faivre-Finn, Lip Lee, Laura Pemberton, Michelle Duffy, Carl Rowbottom
Christie Hospital NHS Foundation Trust; Clinical Oncology Department; Manchester; UK
Introduction: Surgical resection is the optimal curative treatment for early stage non small cell lung
cancer (NSCLC), but only 12% of patients are medically fit for this. Stereotactic radiotherapy (SRT) is
an exciting new technique allowing precise, high dose, hypofractionated RT delivery to the tumour,
while sparing nearby healthy organs. Recent studies indicate that SRT offers local control rates and
survival comparable with surgery.
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SRT is currently not available in any RTcentre in the UK.
Objective/Purpose: We propose to do a feasibility study to facilitate and expedite evaluation and
delivery of lung SRT in the UK
Method: The plan of evaluation includes (1) Evaluation of tumour localisation/definition methods and
feasibility of 4-dimensional CT scans compared to slow CT for RT planning, (2) Evaluation of new
patient immobilisation techniques to improve patients set up (3) Evaluation of Image Guided
Radiotherapy for treatment verification (4) Evaluation of various dose calculation algorithms for SRT
treatment planning (5) Testing delivery of SRT to a phantom to evaluate dose delivered versus
planned to 'tumour' and 'organs at risk' (6) Development of an adaptive planning system for delivery of
SRT.
Results and Conclusion: This background work will establish the most effective working practice for
SRT delivery within the UK, which differs from other countries in terms of workload, resources and
facilities. We are hoping that this feasibility study will facilitate the implementation of this technique in
RT centres equipped with Image Guided RT within the UK and allow participation in international SRT
trials.
OP9
Radiotherapy in extensive-disease small cell lung cancer.
Neil Bayman, Paul Lorigan, Fiona Blackhall, NickThatcher, CorinneFaivre-Finn
Christie Hospital NHS Foundation Trust, Manchester, UK
Introduction: The EORTC 08993-22993 trial showed a survival benefit for prophylactic cranial
irradiation (PCI) in patients who respond to systemic therapy for extensive-disease small cell lung
cancer (EDSCLC). A proposed Dutch Lung Cancer Study Group trial aims to assess the role of
consolidation thoracic radiotherapy (RT) in this setting.
Objective/Purpose: To determine current UK practice in the use of PCI and consolidation thoracic
radiotherapy.
Method: A 10 item questionnaire was sent to clinical oncologists involved in the treatment of small-cell
lung cancer in 52 RTcentres in the UK in December 2007.
Results and Conclusion: 39 centres completed questionnaires (75.0% response). RT is routinely given
following response to systemic chemotherapy in 37 (94.9%) centres (PCI, 35 centres; consolidation
thoracic RT, 14 centres). Prior to the publication of the EORTC 08993-22993 trial in 2007, 5 (12.8%)
centres were using PCI. Most centres (62.9%) aim to start treatment within 6 weeks of completing
systemic therapy. The most common PCI dose/fractionation regimens in use are 20 Gy/5 fractions
(60.0%), 25 Gy/10 fractions (25.7%), and 30 Gy/10 fractions (28.6%). Most centres (79.5%) would be
interested in taking part in a randomised controlled trial to assess the role of consolidation thoracic RT
followinq systemic therapy in EDSCLC. In conclusion, the implementation of PCI followinq the
publication of the EORTC trial has been rapid. We anticipate considerable interest from UK centres in
the proposed consolidation thoracic RTtrial.
OP10
Prospective audit of information, psychosocial needs and symptoms using the LeSS, of lung
cancer patients attending for palliative radiotherapy in a single Institution.
N Mohammed, L Brown
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Introduction / Objectives: Patients are fast tracked for palliative treatment after a new diagnosis of
cancer. The impact of the diagnosis on a patient and their family is in itself traumatic. In addition
communication with the GP can lag behind hospital care.
The aim of this audit was to assess the symptom control, psychosocial and information needs of
patients who attended for palliative radiotherapy (RT). Secondly to assess the feasibility of a follow - up
telephone call.
Method: The study period was from May 06 till November 06. An audit form was developed to facilitate
assessment. The Lung cancer symptom score (LCSS) was used to assess symptoms before and after
RT.
Results: 38 patients were assessed. 58% were male and 32% were aged >80 years.
Performance status was documented as PS 0-1 24%, 1-2 13%, >2 53% respectively. Nineteen patients
died within 3 months of treatment.
Information about the treatment had not been provided (verbal or written) to 37% of patients.
Community support team had not been in contact with the patients or family in 21% of cases. 16% of
patients lived alone with no family nearby for support. Mean LCSS before and after RT were 462 and
437 respectively.
Conclusions: Palliative RT was used to treat mainly frail elderly patients. The GP practice had not made
contact in 21%. The audit successfully identified these patients and their information, financial and
psychosocial needs.
The mean LCSS deteriorated one week after RT indicating the need for back up soon after RT.
OPU
Towards a consistent approach for the prediction of radiation-induced lung toxicity
C Boylan, R Johnston, C Rowbottom, C Faivre-Finn
Christie Hospital NHS Foundation Trust, Manchester, UK
Introduction: Radiation pneumonitis (RP) is the most common dose-limiting complication of thoracic
radiation. Modern planning techniques allow for more conformal dose distributions enabling potential
dose escalation. It is important that robust methods of RP prediction are determined.
Objective/Purpose: Dosimetric parameters suggested to predict the risk of RP include V20 (volume of
normal lung receiving 20Gy or more) and mean lung dose (MLD).
The mean Normalised Total Dose (NTDmean) which corrects for fractionation has also been suggested.
Literature definition of parameters varies with no universally-agreed tolerances. This study examines
treatment plans for patients who received radical radiotherapy for lung cancer and compares the results
of calculating these parameters using differing definitions.
Method: Treatment plans for 50 patients with non-small cell (NSCLC) and small cell
(SCLC) lung cancer patients were retrospectively analysed. NSCLC patients received 55Gy in 20# or
66Gy in 33#. SCLC patients received 66Gy in 33# or 45Gy in 30#. The V20 and MLD were calculated
for all plans using different literature definitions of normal lung: 'both lungs excluding PTV' and 'both
lungs excluding GTV'.
Results/Conclusion: Changing the definition of normal lung volume from ('both lungs - PTV') to ('both
lungs - GTV') increased V20 by a maximum of 8.3 % (mean 4.0%) and MLD by up to 494 cGy (mean
218 cGy). In 6 patients (12%), using an altered definition of normal lung volume resulted in higher V20
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and would potentially result in denying patients radical treatment. The international radiation oncology
community should come to an agreement regarding definitions of V20 and MLD.
OP12
Evaluating target localization and normal tissue irradiation using 4DCT.
Rebecca Muirhead, Carrie Featherstone, Sarah Muscatand Stuart G McNee
The Beatson West of Scotland CancerCentre, Glasgow, UK
Introduction: During planning of radical radiation for non-small cell lung cancer (NSCLC), a planned
target volume (PTV) is created. Respiratory motion is incorporated into this volume by adding a
standard "population-based" margin to the clinical target volume (CTV). Tumour motion differs greatly
between patients and is irrespective of size and location, therefore standard margins for motion are
unreliable. Four-dimensional CT (4DCT) allows the creation of patient-specific margins for tumour
motion in NSCLC.
Objective/Purpose: We aim to compare the planned target volume (PTV) created using helical scans
with standard margins, to a PTV created using 4DCT.
Method: A retrospective analysis of 14 patients who had undergone 4DCT and helical CT for
radiotherapy planning was undertaken. PTVs were created using both scans. These were compared
using ratio of volumes, comparison of centre of mass and overlap of volumes. Radiotherapy plans were
also drawn up for comparison.
Results and Conclusions: In most patients the intra-fraction motion was overestimated by the standard
margins and PTV_HELICAL was larger than PTV_4DCT. The ratio of volumes (PTV_HELICAL /
PTV_4DCT) was 1.25 (range 0.88 - 1.36). The mean of unnecessary tissue irradiated using the
PTV_HELICAL was 22.78% (range 7.80% - 34.56%). In the patient who had the most tumour
movement however, the PTV_HELICAL was too small and 18.32% of the tumour volume was
uncovered. In summary 4DCT is required to individualize the margin for tumour motion. This improves
localization of tumour tissue and reduces normal tissue irradiation. This should collate with improved
local control and reduced morbidity secondary to radiotherapy.
OP 13
Quality of life after radiotherapy and steroids in patients with inoperable brain metastases
from NSCLC:The QUARTZ trial
Paula Mulvenna 1, Rachael Barton 2, Cheryl Pugh 3 and Richard J Stephens 3.
1 Newcastle General Hospital, NCCT, Newcastle; 2 Princess Royal Hospital, Hull; 3 MRC Clinical Trials
Unit, London
For patients with inoperable brain metastases the standard therapy is a combination of steroids and
whole brain radiotherapy (WBRn. However, WBRT causes side effects and has never been shown to
correlate with improved quality of life or length of survival. Therefore, it is uncertain whether those
clinicians who treat this group of patients should continue to include WBRT within the package of
optimal supportive care (OSC) offered via the multidisciplinary team. OSC includes dexamethasone
titrated to clinical effect to the lowest dose possible The QUARTZ trial compares OSC with OSC plus
WBRT in the treatment of patients with inoperable brain metastases from NSCLC. The primary outcome
will be a comparison of QALYs (Quality Adjusted Life Years) to reflect the balance between the need to
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maintain or extend survival and improve quality of life. Data for the QUARTZ trial are collected via
weekly telephone assessments between the patient (and carer if consented for
participation) and their nurse using a questionnaire including the EQ-5D, EQ-VAS and a list of
symptoms.
QUARTZ is now open to recruitment with 57 UK centres (as well as 3 centres from TROG (Trans
Tasman Radiation Oncology Group in Australia)), with a further 10 centres organising relevant
submissions. Updated recruitment and compliance with the weekly collection of data will be presented,
which to date has proved very successful. For more details or to register your centre's interest please
contact OUARTZ@ctu.mrc.ac.uk.
OP14
Prognostic Impact of Standardized Uptake Value on 18F-FDG Positron Emission
Tomography in Small Cell Lung Cancer
Young Joo Lee M.D.1, 2, Hye Jin Choi M.D.1, 2, Joo Hyuk Sohn M.D.1, 2, Joo Hang Kim, M.D, Ph.D.1, 2
1Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea;
2Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea;
Introduction: Prognostic factors in small cell lung cancer (SCLC) include tumor stage, LDH, NSE, and
sex. However, prognostic importance of SUV value in 18F-FDG PET scan is unclear Objective. We
investigated prognostic significance of SUV on PET in survival of SCLC patients.
Methods: Between 2002 and 2007, newly-diagnosed SCLC patients who received the standard
treatment after PET or PET/CT were eligible. We measured maximal SUVs (SUVmax) of all malignant
lesions. Patients within each stage were divided to four groups according to quartiles of total mean
SUVmax Result. 53 patients were analyzed; limited disease (LD) (n=30) and extensive disease (ED)
(n=23). The median follow-up time was 13.6 months.
Mean SUVmax showed strong association with two-tiered stage (8.8±5.5 vs.
13.1±7.6, P = 0.0008). A multivariate analysis for overall survival identified mean SUVmax (P = 0.03),
tumor stage (P = 0.036), and response rate (P = 0.017) as significant. Mean SUVmax was associated
significantly with worse progression free survival&#12308;in LD, low SUV «7.1) = 19.1 months vs.
high SUV (&#8805;7.1) = 9.6 months, P < 0.0001; in ED, low SUV «10.4) = 6.0 months vs. high SUV
(&#8805;10.4) = 3.1 months, P = 0.04&#12309;. Mean SUVmax was associated significantly with
worse overall survival (P = 0.04 in LD and P = 0.03 in ED). There was no significant difference in
survival between the highest quartile of SUV in LD and the lowest quartile of SUV in ED.
Conclusion: Metabolic staging by mean SUVmax on pretreatment PET have high prognostic impact in
SCLC.
OP15
The impact of PETI CT on radiotherapy planning in lung tumors
Jamal SK, Ali HH, Farid YR, Fayez AW,
King Hussein Cancer Center, Radiation Oncology Department, Amman, Jordan.
Introduction: Positron emission tomography (PET) has been accepted as a valuable tool for the staging
of lung cancer, but the use of PET/CT in radiation treatment planning is still not yet clearly defined.
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Objective/Purpose: To report a prospective study concerning the impact of co-registering PET/CT
imageswith CT imageson the planning target volume (PTV)
Method: Twenty nine patients with poorly defined tumors on CT,were referred for radical radiation
therapy. Following CT simulation, PET/CT scanning was performed in the treatment position.Standard
margins were applied to each gross tumor volume to generate a PTV.The CT and PET/CT transmission
images were then registered in the treatment planning system. The PTV was modified using the
registered PET /CT emission images. The modified PTV is seen simultaneously on both CT and PET/CT
images, allowlnq the radiation oncologist to define the PTV utilizing the information from both data
sets.Dose-volume histograms were used to evaluate the effect of PET/CT information on PTV and on
normal tissue dose.
Results & Conclusion: PET/CT identified previously undetected distant metastatic disease in 3 patients,
making them ineligible for radical conformal radiotherapy. The GTV reduction was in 7 patients
because CT-PET image fusion reduced the pulmonary GTV in 3 patients and in 4 patients with
atelectasis.The GTV increase was in 10 patients due to an increase in the pulmonary GTV in 6 patients
and detection of occult mediastinal lymph node involvement in 4 patients.The results of our study have
confirmed that integrated PET/CT have an impact on radiotherapy treatment planning.
OP16
The prognosis of completely resected p-stage IA non-small cell lung cancer: implications
for adjuvant therapy
Masahiko Harada, Manabu Yamamoto, Hirotoshi Haria
Division of Thoracic Surgery, Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JAPAN
Background: Non-small cell lung cancer (NSCLC) patients with pathological stage IA disease have the
best chance of cure by surgery alone. Within the stage IA designation, however, there may be patient
characteristics that influence worse long-term survival. Furthermore, therapeutic strategy still remain
controversial in the group having poor prognostic factors. In the present study, we attempted to clarify
the prognostic factors based on the survival.
Methods: Between January 1990 and December 2005, 337 patients were eventually given a diagnosis
of p-stage IA NSCLC. Ten clinicopathologic factors, namely age, gender, primary location,
histopathology, differentiation, tumor size, pleural involvement, vessel involvement, lymphatic
involvement and extent of surgical resection, were investigated by univariate and multivariable analyses
to identify significant prognostic factors among resected p-stage IA disease. For the univariate analysis,
we constructed survival curves using the Kaplan-Meier method and compared survival between groups
using log-rank tests. Multivariable analysis was performed by constructing a Cox proportional hazards
model using the significant factors from the univariate analysis. The analyses were performed with the
Stat view v5.0 statistical software program.
Results: The overall 5-year survival was 83.4%. Univariate analysis among overall patients revealed 8
significant prognostic factors (P <.05): age, gender, primary location, differentiation, pleural
involvement, vessel involvement, and lymphatic involvement. Based on the result, 5-year survival rate
in each factor were compared statistically by Kaplan-Meier's method; <70 vs. >70 = 89.2% vs. 74.6%
(p=0.0035), female vs. male = 86.4% vs. 80.8% (p=0.0107), right vs. left = 87.7% vs. 77.1%
(p=0.0339), Ad. vs. non-Ad. = 87.3% vs. 72.3% (p=0.0002), well vs. non-well. = 88.9% vs.
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77.1% (p=0.0003), p+ vs. p- = 71.7% vs. 86.1% (p=0.0450), Iy+ vs. Iy- = 69.8% vs. 88.7%
(p=0.0002), v+ vs. v- = 74.6% vs.87.5% (p=0.0049). The patients with Iy+ and v+ factors have very
low 5-year survival compared with patients with Iy- and v- factors (eg. 89.7% vs. 66.3% (p=0.0002).
Multivariable analysis revealed age, primary location, differentiation, and lymphatic involvement
remained statistically significant. The hazard ratio for death for being under 70 years was 0.559
&#12304;95%CI 0.325-0.959&#12305;(p=0.0347), for having left side tumor was 2.008
&#12304;95%CI 1.175-3.430&#12305;(p=0.0107), for having non-well differentiation was 1.886
&#12304;95%CI 1.039-3.424&#12305; (p=0.0371), and for having no lymphatic involvement was
0.408 &#12304;95%CI 0.232-0.719&#12305; (p=0.0019).
Conclusions: This study identifies 4 factors that may affect survival in resected stage IA non-small cell
lung cancer. Some patients having poor prognostic factors may benefit from adjuvant chemotherapy.
OP 17
THE MULTIDISCIPLINARY TEAM MEETING IN LUNG CANCER
Craig Martin, Maria Cremin, Tom Roques, Karen Noonan-Shearer, Adrian Harnett, Ann Barrett
Introduction: The multidisciplinary team meeting (MDTM) has become standard throughout UK since
1995, yet there is little hard evidence as to its value.
Objective: To assess how frequently the lung cancer MDTM affected the management plan in our
centre.
Methods: In patients presenting over a 4-month period, demographic and tumour data were recorded,
details of the MDTM: personnel involved in discussion, time and management plan pre-MDTM (Tl),
post-MDTM (T2) and after discussion with the patient (n).
Results: 55 patients were discussed, 5 excluded (inadequate data), ages 51-90.
Histology: NSCLC 41, SCLC 5, clinical cancer 1, mesothelioma 2
2-8 team members took part in discussion, 4 or more in 88% discussions, median time 4.7 minutes.
Treatment intent pre-MDTM was: curative 18%, palliative 59%, undecided 22%, while post-MDTM was
35%, 65% and 0% respectively.
In 20% there was a change of treatment plan and in 22% no plan was changed to a definite plan.
Final treatment intent at n was predicted correctly by 63% of presenting doctors and by 92% of
MDTM decisions. However exact treatment plan was correctly predicted by only 24% of presenting
doctors and 59% of MDTMs.
Conclusions: The final treatment plan is often different from that proposed by either the referring
physician or the MDTM.
While the MDTM has a major role in education, team-bulldinq and shortening patients' pathways, its
role in decision-making needs further research.
OP 18
Review of CHART for NSCLC in the West of Scotland
BrianJ Clark, Carrie Featherstone
Beatson West of Scotland Cancer Centre, Glasgow, Scotland
Introduction: Continuous hyperfractionated accelerated radiotherapy (CHART) has theoretical
radiobiological advantages over conventional fractionation schedules for non-small cell lung cancer
(NSCLC). CHART was introduced routinely at the Beatson West of Scotland Cancer Centre in June 2004.
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Objective: We report a retrospective audit of our first two years' experience of CHART for NSCLC in the
West of Scotland.
Methods: Patient demographics, tumour characteristics, treatment details, incidence of pneumonitis and
survival data were collected for all patients booked to receive CHART for NSCLC from June 2004 until
May 2006. Results: 74 patients were booked to receive CHART, of which 67 were treated. Median
follow-up was 30.7 months. Overall median survival was 19.6 months.
t-vear and 2-year survival were 65.9% and 33.5% respectively. A trend towards improved survival was
seen in younger patients and in those with performance status 0-1. Median survival was 15.1 months
for patients with squamous histology compared with 24.7 months for non-squamous or unknown
histology. After treatment, symptomatic pneumonitis was reported in 17.9% of patients. Those who
developed pneumonitis had 2-year survival of 11.2% compared with 40.3% in patients without
pneumonitis. No treatment-related parameterswere found to be predictive of pneumonitis.
Conclusion: Our results show similar survival compared to previously published trials and other
published series. In our series, older age, poor performance status, squamous histology and
development of pneumonitis were associated with poorer survival. Careful patient selection is important
when considering CHART as an alternative to conventional radiotherapy.
OP 19
Longer-term quality of life following surgery for NSCLC
Penelope Hopwoodl, David Gilligan2, Marianne Nicolson3, Matthew Nankivell4, Cheryl Pugh4, Richard
Stephens4
IPsycho-Oncology Service, Christie Hospital NHS Trust, Manchester, UK; 2Clinical Oncology,
Addenbrookes Hospital, Cambridge, UK; 3Aberdeen Royal Infirmary, Aberdeen, UK; 4MRC Clinical Trials
Unit, London UK
There is a paucity of data relating to the longer-term quality of life (QL) of patients undergoing
potentially curative treatment for non-small cell lung cancer. QL evaluation was therefore integrated
into the LU22 randomised trial to assess and compare the QL of patients receiving surgery alone (S) or
pre-operativechemotherapy (CT-S).
All patients completed the SF-36 questionnaire prior to randomisation, at 6 and 12 months, and
annually to 5 years.
519 patients were entered into the trial, and 244 have died, but there was no evidence of a survival
benefit with pre-operative chemotherapy (HR 1.02). At 6 months the 2 treatment groups reported
comparable functioning in 7 of the 8 SF-36 domains, but the S group reported statistically significantly
better Role Functioning. No statistical differences were observed at 12 or 24 months. Regression
analyses indicated that better baseline physical and mental health, longer time from surgery and
younger age predicted better longer-term physical health, and better baseline mental health, female
gender and younger age predicted better longer-term mental health. Treatment regimen had no effect
on QL at any follow-up point. 39% of patients rated their health as excellent or very good at baseline,
but this dropped to 26% at 6 months and remained at a similar level thereafter. More than 50% of
patients considered their health comparable to others and over 45% were generally optimistic about
their future health.
Most patients maintained good QL following curative treatment for NSCLC, although about a third did
not recover to baseline levels post-treatment.
Copyright © 2008 by the International Association for the Study ofLung Cancer
Journal of Thoracic Oncology • Vol. 3, No.7, Supplement 3, July 2008 l " International Lung Cancer Conference
OP20
The Northern Cancer Network Experience: Docetaxel in NSCLC
Louise Li, Eleanor Aynsley, Jill Gardiner, Rhona McMenemin and Andrew Hughes
Northern Centre for Cancer Treatment, Newcastle General Hospital, Newcastle upon-Tyne, United
Kingdom
Introduction: Approximately 70% of non small cell lung cancer (NSCLC) patients present with advanced
disease. Treatment intent is palliative. Patients often receive chemotherapy and/or radiotherapy as
first line treatment. Upon progression of disease, second line chemotherapy is considered. In the UK,
Docetaxel is the only NICE approved drug in this setting. Scepticism remains amongst Oncologists over
its efficacy and toxicity, especially with the advent of the licensed alternatives, Erlotinib and
Pemetrexed.
Objectives: The objectives were to record population and disease demographics of NSCLC patients
receiving Docetaxel in a second line setting, clinical efficacy and toxicity profile.
Method: A retrospective, multi-centre audit was performed in the Northern Cancer Network. Patients
were identified by databases from Consultants, Pharmacists and computer systems. Data were
captured from medical notes.
Results & Conclusions: 67 patients with NSCLC received Docetaxel between 2002 and 2007. The
median age was 61 years (range 39-81). Most patients had advanced disease at presentation - Stage
3B (26.9%) and Stage 4 (53.7%). The median number of cycles was 2 (range 1 to 6). A range of
toxicities was seen, the most common being fatigue (52.2%). The rate of febrile neutropenia was
12%. The partial response rate was 17.9%, stable disease 26.9% and progressive disease 41.8%
(13.4% could not be evaluated). Median survival was 7.5 months (n=62).
The results are comparable to published data on survival and toxicity from
TAX 3171• Docetaxel is active, reasonably tolerated and is an option in NSCLC for second line
treatment.
References:
1. Shepherd et al. Prospective Randomised Trial of Docetaxel Versus Best Supportive Care in Patients
with Non Small Cell Lung Cancer. J Clin Oncol
18: 2095-2103, 2000.
OP2l
Social and travel factors and treatment of lung cancer
S Michael Crawford1, Violet Sauerzapf2, Robin Haynes2, Hongxin Zhao2, David Foreman3, Andrew P
Jones2
1 Airedale General Hospital, Keighley, BD20 6TD UK; 2 School of Environmental Sciences, University of
East Anglia. Norwich, UK; 3 Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, UK.
Introduction: UK residents have access to healthcare free of charge but uptake varies. A recent analysis
within a large project which exploring the relationship of geographical factors to cancer outcomes,
(Jones AP et ai, Travel time to hospital and treatment for. cancer. Eur J Cancer. 2008 Epub ahead of
Copyright © 2008 by the International Association for the Study ofLung Cancer 8217
I" International Lung Cancer Conference Journal of Thoracic Oncology • Vol. 3, No.7, Supplement 3, July 2008
8218
print) demonstrated distance decay for access to radiotherapy for many cancers and to surgery for lung
cancers.
Purpose: We report the interaction of social deprivation and travel time to the nearest hospitals
providing services on the odds of receiving interventions.
Methods and Results: Using a database of 34,923 lung cancer patients from the Northern & Yorkshire
Cancer Registry & Information Service. Patients were assigned to quartiles for the deprivation score
associated with their postcode and for travel time to the facility. Odds ratios, adjusted for age and sex,
for undergoing interventions relative to least deprived
quartile llvinq closest to facility (*p<0.05 **p<O.Ol) were:
histological diagnosis (A) Least deprived/furthest residence 0.83*, (B) Most deprived/nearest 0.74**
(C) Most deprived/furthest 0.61**. Receipt of active treatment, (A) 0.93, (B) 0.74** (C) 0.55**.
Chemotherapy for SCLC (A) 1.24, (B) 1.19 (C) 0.74. Surgery for NSCLC using (1) travel time to
diagnosing hospital (A) 0.88 (B) 0.74* (C) 0.60** (2) travel time to thoracic surgery (A) 0.84 (B) 0.77*
(C) 0.60**
Conclusions: Living in a deprived locality reduces the likelihood of undergoing definitive management
for lung cancer with the exception of chemotherapy for small cell lung cancer. This effect is amplified
by travel time to services.
OP22
Best Supportive Care in lung cancer trials: clinical and cost comparisons
Authors: Boland A1, McLeod C1, Jack B2, Stevenson J3 and Dickson R1
1. Liverpool Reviews and Implementation Group (LRiG), Department of Pharmacology, University of
Liverpool, Liverpool UK 2. Edge Hill University, Faculty of Health, University Hospital Aintree, Longmoor
Lane, Liverpool L9 7LN/ Marie Curie Palliative Care Institute, Speke Road, Liverpool L25 8QA
3. Marie Curie PalliativeCare Institute, Speke Road, Liverpool L25 8QA
Introduction: In cancer trials, chemotherapy treatments are compared with packages of best supportive
care (BSC). However, the packages of BSC offered, and then delivered, to patients in trials are often
not clearly defined.
Objective: We set out to identify and discuss the clinical components of BSC for patients with lung
cancer to help inform the future conduct of cost-effectiveness analyses (CEA).
Methods: Systematic review of RCTs, systematic reviews (SR) and economic evaluations (EE) which
compare chemotherapy with BSC for adult patients with lung cancer.
Results: 26 RCTs, 13 SRs and 41 EE met the review inclusion criteria. Less than 50% of relevant studies
included formal definitions of BSe. The included studies did not adequately describe or outline either
the components or the delivery of BSC for patients in lung cancer trials. None of the studies provided a
clear definition of a patient pathway in relation to BSC or an explicit list of components or costs of such
care.
Conclusions: Clinical and costs comparisons of BSC within and across trials are problematic. Formal
definitions of BSC with set parameters for the common complications of advancing disease, not just the
physical symptoms, need to be established to inform CEAs. From an ethical perspective, patients in
trials require adequate definitions of the care they could expect to receive. Health care professionals
involved in the conduct and reporting of cancer trials must aim to communicate the BSC package
delivered to patients.
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OP 23
Chemoprevention of Kava on Lung Tumorigenesis
Thomas E. Johnson1, Fekadu Kassie2, Gerard O'Sullivan2, Mesfin Negia2, Timothy Hanson3, Pramod
Upadhyaya2, Peter P. Ruvolo4, Stephen S. Hecht2, and ChengguoXing1
1 Department of Medicinal Chemistry, University of Minnesota, MinneapolisMN 55455
2 CancerCenter, University of Minnesota, Minneapolis MN 55455
3 Department of Biostatistics, University of Minnesota, MinneapolisMN 55455
4 Hormel Institute, University of Minnesota, Austin MN 55912
Lung cancer is the leading cause of cancer death and chemoprevention is a potential strategy to control
this disease. Epidemiological information indicates that kava may be chemopreventive against lung
cancer while its potential hepatotoxicity is a concern. In this study, we evaluated whether oral kava
could prevent NNK and B[a]P-induced lung tumorigenesis in the AIJ mouse. We also studied the
potential hepatotoxicity of kava.
At a dose of 10 mglg diet, 30-week kava treatment (8 weeks concurrent with NNK and B[a]P treatment
followed by 22 weeks post-carcinogen treatment) effectively reduced lung tumor multiplicity by 56%.
Kava reduced lung tumor multiplicity by 47% when administered concurrently with NNK and B[a]P.
Perhaps most importantly, kava reduced lung tumor multiplicity by 49% when administered after the
final NNK and B[a]P treatment. These results clearly demonstrate the chemopreventive potential of
kava against lung tumorigenesis. Mechanistically, kava inhibited proliferation and enhanced apoptosis
of lung cancer cells as demonstrated by a reduction of Proliferating cell nuclear antigen (PCNA), an
increase of caspase-3 and cleavage of Poly (ADP-ribose) polymerase (PARP). Kava treatment inhibited
the activation of nuclear factor-&#1082;B (NF-&#1082;B), a potential up-stream pathway of kava
chemoprevention. No hepatotoxicity was detected among the mice treated with kava, suggesting that
oral kava consumption is safe. Thus, for the first time, we demonstrate that oral kava is safe and
prevents lung tumorigenesis, which could be mediated via inhibition of NF-&#1082;B activation,
resulting in a suppression of proliferation and an increase of apoptosis in lung tumors.
OP24
Defining the REST-regulome in neuroendocrine lung cancer
Judy M. Coulson1, Brian S. Lane2, Lauren E. Walker1, Gregory M. Jacobson1
lUniversity of Liverpool, School of Biomedical Sciences, Liverpool, UK;
2University of Liverpool, Northwest Institute for Bio-Health Informatics (NIHBI), Liverpool, UK.
Introduction: The candidate tumor suppressor RE-1 silencing transcription factor (REST/NRSF) is a
transcriptional repressor that is functionally lost in neuroendocrine small cell lung cancer (SCLC).
Objectives: To delineate the role of REST we analyzed transcriptional profiles following conditional
depletion of endogenous REST in human non-neuroendocrine lung cancer cells.
Methods: REST protein was depleted with two siRNAs and compared to two non-targeting sequences.
RNA from triplicate experiments were hybridised to Affymetrix HG-U133 Plus2.0 DNA chips and data
analysed in GeneSpring. Candidates were validated by qRT-PCR; transcriptional regulatory mechanisms
and functional significance were investigated.
Results and Conclusion: REST siRNA induced 184 transcripts by >2-fold and
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729 transcripts by > 1.5-fold (P<0.05) including novel REST targets. 24% of induced genes were also
over-represented in SCLC. Gene ontology analysis confirmed a role in neurosecretory processes and
controlling other transcriptional regulators, but suggested REST also contributes to many processes
germane to cancer including cell cycle, motility, communication, proliferation and death. Interestingly
83 transcripts were also repressed >2-fold in response to REST depletion (P<0.05) with roles in
metabolism, transcription, splicing and cell cycle. RE1 motifs were predicted for 68% of induced and
37% of repressed genes, whilst 17% and 30% respectively were potential targets for 8 REST-induced
miRNAs. Not all genes with delineated REST binding motifs were dysregulated and the transcriptional
basis for this was investigated. Thus in lung cancer, we show that REST controls not only absolute
repression of neuroendocrine genes, but also subtle changes in extensive oncogenic transcriptional
programs.
OP 25
Clinical importance of cleaved uPAR forms in NSCLC
Charlotte E Almasi1, Gunilla Hever-Hansent, Ib J Christensen1, Helle Pappotl,2
1 The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark;
2 Department of Oncology, Rigshospitalet, Copenhagen, Denmark
Introduction: The urokinase plasminogen activator (uPA) system is an extracellular protease system,
active during cancer invasion. A key-role is played by uPA receptor, uPAR, consisting of three domains
denoted I, II and III. uPA cleaves uPAR between domain I and II and the levels of cleaved uPAR forms
may reflect the activity in the uPA system.
Purpose: To analyse the associations between of intact and cleaved uPAR forms in body fluids and
tumour tissue from NSCLC patients as well as the prognostic impact of these.
Methods: Thirty-four patients surgically resected for NSCLC were included.
Preoperatively sampled plasma/serum was available from 32, urine from 29 and tumour tissue extracts
from 24 of these. The levels of the different uPAR forms in the samples were measured by 3 different
TR-FIA's. In urine and tumour extracts only uPAR(I) could be measured.
Results: Plasma and serum levels of uPAR(I-III), uPAR(I-III)+uPAR(II-III), and uPAR(I) were
correlated, and always higher in serum. Spearman's correlations, rs between urinary uPAR(I) and
uPAR(I) in plasma/serum, and between urinary uPAR(I) and tumour extracts were 0.55/0.42 and 0.22,
respectively. uPAR(I) in tumour extracts was not correlated to uPAR(I) in plasma/serum. In survival
analysis adjusted for histology, high levels of uPAR(I-III) and uPAR(I) in plasma and uPAR(I) in serum
were significantly associated to short overall survival (HR=4.31, c.i.: 1.10-16,83, HR=2.83, c.i.:1.14-
7.05 and HR=3.78, C.i.: 1.44-9.90 respectively).
Conclusions: High levels of both intact and cleaved uPAR forms in blood were significantly associated
with short overall survival. These findings need verification in a larger population.
OP26
Tie2 driven overexpression of cal reticulin induces lung adenocarcinoma
Behzad Yeganeh, Melanie M. Durston, Jeffrey Wigle and Nasrin Mesaeli
Institute of Cardiovascular Sciences, St. Boniface Research Centre, and Department of Biochemistry and
Medical Genetics, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
Copyright © 2008 by the International Association for the Study ofLung Cancer
Journal of Thoracic Oncology • Vol. 3, No.7, Supplement 3, July 2008 l " International Lung Cancer Conference
Calreticulin (CRT) is a multifunctional Ca2+ binding chaperone, localized to the endoplasmic reticulum.
In addition to its critical role in cardiovascular development, CRT has been reported to be important in
cell migration, apoptosls, and cancer cell growth. Several proteomic studies have shown an increase in
CRTexpression in different human cancers.
Therefore, the aim of this study was to investigate the in vivo role of CRT in the development of cancer.
We generated a transgenic mouse over-expressing CRTunder the control of
Tie2 promoter (Tie2-CRT) which is active in both endothelial cells and hematopoietic stem cells. The
early phenotype of Tie2-CRT mice is localized hemorrhagic lesions in different tissues, accompanied by
increased vessel fragility. With age, the main phenotype of these mice is development of spontaneous
lung adenocarcinoma (over 90%). Our histological studies show that lung tumour in the Tie2-CRT mice
is arising from the peripheral airway preceded by sequences of morphological changes including mild
congestion, accumulation of inflammatory cells and atypical adenomatous hyperplasia in peripheral
airway cells. As the lesions progressed, they formed small and peripheral tumour with a glandular and
papillary structure resembling human pulmonary adenocarcinoma.
Immunohistochemical staining revealed that the tumour are made of heterogenous pool of CRT-HA+ve,
CD34+ve, c-kit+ve, CD133+ve, CC10-ve, SPC-ve cells and CRT-HA-ve, CD34-ve, c-klt-ve, CC10-ve,
SPC+ve. In conclusion, overexpression of CRT under the control of Tie2 increases the incidence of lung
tumour in mice. This is the first report on an association between induced overexpression of CRT and
the development of lung tumour.
OP27
Mechanism of NNK-induced lung cell proliferation
George G Chen, Ming-Yue Li, Johnson Yip, Michael KY Hsin, Malcolm J Underwood
The Chinese University of Hong Kong, Surgery, Shatin, Hong Kong
Introduction: 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific
nitrosamine, induces lung cancer in all animal species tested and contributes significantly to the
development of smoking-related lung cancer. The molecular carcinogenic mechanism of NNK is not fully
known.
Objective/Purpose: To explore how NNK promotes the proliferation of lung cancer cells.
Method: HO-1 (heme oxygenase 1) and p21 in NNK-treated lung cancer cells and in 30 lung tumor
samples of the smokers were examined.
Results and Conclusion: HO-1 and p21 were significantly increased in lung tumor tissues. NNK
stimulated the proliferation of lung cancer cells, elevated the levels of HO-1, p21, c-IAP2 and BcI-2, but
down-regulated Bad. ZnPP XII a HO-1 specific inhibitor not only inhibited NNK-induced
HO-1 expression, but also down-regulated p21 and c-IAP2 and blocked the nuclear p21 induced by
NNK. NNK enhanced NF-kappaB activity by translocating p65 into the nucleus and inducing the NF-
kappaB DNA binding activity. NNK also promoted ERK activation. The effect of NNK on the NF-kappaB
was blocked by not only SN50, an inhibitor of NF-kappaB, but also by U0126, an inhibitor of ERK. Unlike
U0126, NNK-mediated increased ERK activation was suppressed by U0126 but not by SN50. Inhibition
of ERK and NF-kappaB activation down-regulate NNK-mediated HO-1, p21, c-IAP2 and BcI-2
expression.
In conclusion, lung cancer tissues are associated with increased HO-1 and p21. NNK enhances the level
of HO-1 via activating ERK and NF-kappaB, and subsequently it promotes the nuclear p21, up-regulates
c-IAP2 and BcI-2 and down-regulates Bad.
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OP28
Significance of Id family proteins in Small Cell Lung Cancer
Laleh Kamalian, John R. Gosney, Shiva S. Forootan, Christopher S. Foster, Zheng Z. Bao, Carol Beesley,
and Youqiang Ke
Molecular Pathology Laboratory, School of Cancer Studies, Faculty of Medicine, the University of
Liverpool, Liverpool, L69 3GA, United Kingdom.
Introduction: The expression of Inhibitors of differentiation /DNA binding
(Id) proteins, a group of basic Helix-Loop-Helix transcription factors, key regulators of cell growth and
differentiation with proven tumourigenic properties, was studied in small cell lung cancer (SCLC).
Purpose: Molecular pathology methods were used to identify candidate genes involved in malignant
progression of the cancer cells.
Methods: Micro-quantity differential display (MDD) was used initially to identify genes expressed
differentially between normal and malignant cell lines. The differences were verified by Western blot.
Immunohistochemical analysis was performed on paired normal and malignant lung tissues and on
biopsy specimens to assess the expression status of candidate genes and their prognostic significance.
Result and conclusion: Id1 gene was up-regulated in SCLC cells. Levels of Id1 in 8/10 malignant cell
lines were increased by 1.7- to 21.4- fold comparing to the benign cells. A similar increase was found in
levels of Id2 and Id3. On 26 pairs of lung tissues; all four Id proteins were significantly (Wilcoxon
Signed Rank Test, p<O.OOl to p<O.OOS) overexpressed in cytoplasm of the malignant cells. In nuclei of
SCLC cells, Id1 expression was significantly reduced, whereas the levels of Id2, Id3 and Id4 were
significantly (p<O.OOl) increased. Immunohistochemical staining on biopsy specimens showed that high
level of Id2 in cytoplasm of cancer cells, not the other three proteins, was significantly associated with
the increased survival of SCLC patients. Changed expression profiles of Id proteins may play important
roles in malignant progression of SCLC and the increased Id2 in cytoplasm is a novel prognostic factor
to predict the patient outcomes.
OP29
Expression of Id-lb, an alternative splicing isoform of Id-l, decreases lung cancer cell
malignancy and is significantly reduced in lung tumors
Paul Nguewa1, David Blanco1, Ignacio GiI-BalO1, Roque Diaz1, Oscar Gonzalez-Moreno1, Diego
Serrano1, Raul Catena1, Carlos Garcia Franco2, Celia Piror1, Miriam Redrado1, Luis Montuenga1,
Alfonso Calvo1
lDivision of Oncology, CIMA, and 2Department of Thoracic Surgery, University Hospital of Navarra,
University of Navarra, Pamplona, Spain
Id-1 is a member of the helix-loop-helix family of proteins that regulates the activity of transcription
factors to suppress cellular differentiation and promote cell growth. Overexpression of Id-1 in tumor
cells correlates with increased malignancyand resistance to chemotherapy and radiotherapy.
Id-1b is an Id-1 lsoforrn generated by alternative splicing that differs from Id-1 in the 13 C-terminal
aminoacids. Id-1b regulates the transcription binding specificity of Id-1. We have quantified by real
time RT-PCR expression levels of Id-1 and Id-1b in 13 non-small cell lung cancer specimens and their
matched normal counterparts. In addition, we have overexpressed Id-1b in AS49 cells to study the role
of this lsoform in lung cancer. Expression levels of Id-1 did not change in lung tumors compared to
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normal tissues. On the contrary, a significant down-regulation in the expression of the isoform Id-1b
was found in tumors (p<0.02) with respect to normal samples. A549 cell clones stably transfected to
ovexpress Id-1b showed a significantly reduced proliferation activity and c1onogenic potential than
control cells. Moreover, Id-1b overexpressing cells treated with 4Gy irradiation dose were significantly
less resistant to cell death. Our results demonstrate that the two alternative spliced isoforms play an
opposite role, where Id-1b decreases malignancy of lung cancer cells and sensitizes to radiotherapy-
induced cell death. Since the expression of Id-1b is consistently reduced in lung tumors, analysis of Id-
1b mRNA levels could represent a novel potential biomarker of lung cancer.
OP30
Lung Cancer DSAi A Platform for Discovery of Biomarkers in Lung Ccancer
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide with poor
differential diagnosis of the disease and with low response rates to standard chemotherapy treatment.
It is therefore a subject of extensive research focused on identification of reliable genomics biomarkers
to aid in accurate classification of the disease, predicting its progression and patients' response to both
available therapies and those in development. Powerful genomics tools used in this research are
however lacking disease focus and thus are likely to miss potentially vital information contained in
patients' tissue samples.
Through a combination of large-scale in-house sequencing, gene expression profiling and public
sequence and gene expression data mining we have characterised the transcriptome of NSC lung
cancer and used this information to create a unique disease focused microarray - Lung Cancer DSA
research tool. Built on the Affymetrix GeneChip platform the tool allows for interrogation of "'60,000
transcripts relevant to Lung Cancer, tens of thousands of which are unavailable on leading commercial
microarrays. Presented here are the array design process and the results of experiments carried out to
demonstrate the array's utility for use in biomarker discovery projects with using NSCLC and normal
samples.
OP31
Integrative Genetic and Epigenetic Analysis of Lung Tumor Genomes
William W. Lockwood1, Ian Wilson1, Raj Chari1, Bradley P. Coe1, Timon P. H. Buys1, Chang Qi Zhu2,
John C. English1, John Yee1, Ming-Sound Tsa02, Calum MacAulay1, Stephen Lam1 and Wan L. Lam1
1British Columbia Cancer Agency, Vancouver, Canada 20ntario Cancer Institute/Princess Margaret
Hospital, Toronto, Canada
Introduction: It is currently believed that multiple DNA alterations are required for lung cancer (LC)
initiation. These include genetic changes such as gain and loss of chromosome segments, as well as
epigenetic changes such as aberrations in DNA methylation patterns. To date, there have been no
studies simultaneously tracking global genetic and epigenetic alterations in LC in order to associate
such alterations with specific disease phenotypes.
Objective: To comprehensively characterize the underlying molecular alterations driving LC
development using an integrative genomic and epigenomic analysis.
Method: A whole genome tiling path comparative genomic hybridization (CGH) array was used to
generate high resolution copy number (CN) profiles of 181 lung tumors and bronchial carcinoma in situ
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lesions. Whole genome DNA methylation status was assessed by methylation dependant
immunoprecipitation array CGH.
Results and Conclusions: Numerous CN and DNA methylation changes were identified by generating
parallel genomic and epigenomic profiles from individual lung tumors. In addition to identifying novel
regions of recurrent DNA gain or loss, we also observed a high degree of genomic instability for most
cases, with some tumors displaying multiple segmental alterations within individual chromosome arms.
Interestingly, LC histopathological subtypes were seen to harbor distinct patterns of CN and
methylation changes, reflecting differences in their development. Lastly, concerted regions of DNA
hypermethylation and segmental loss, as well as hypomethylation and gain signified novel two hit
mechanisms for both gene silencing and activation respectively. The discovery of these novel gene
alterations sheds light on the mechanisms driving lung tumorigenesis and identifies new molecular
targets for targeted therapies.
OP32
Identification of human lung tumor initiating cells
Giulia Bertolini, Graziella Pratesi, Luca Roz, Anna Livio, Monica Tortoreto, Alessandra Fabbri , Enrico
Fontanella, Francesca Andriani, Delia Domenico, Ugo Pastorino, Gabriella Sozzi
Cytogenetics and Molecular Cytogenetics Unit Department of Experimental Oncology Fondazione IRCCS
Istituto Nazionale Tumori Via Venezian 1, 20133 Milan, Italy
Introduction: There is increasing evidence that tumors are organized as a hierarchy originating from
stem-like cells responsible for tumor maintenance. Tumor initiating cells can be identified through the
expression of stem cells markers as CD133, as described in brain, prostate, colon and lung cancer.
Purpose: The isolation and characterization of human lung cancer initiating cells might provide new
possibilities for prognosisand therapy of lung cancer.
Methods: To investigate the existence of a population of tumor initiating cells in non small cells lung
cancer (NSCLC), we analyzed the expression of the stem-associated CD133 antigen in the A549
adenocarcinoma cell line, in primary tumors and in tumor xenografts established in
immunocompromised mice and we evaluated the tumorigenic potential of CD133 positive cells.
Results: A subpopulation of CD133-EpCAM positive cells was detected by flow cytometry in 63 analyzed
tumors. This population accounted for about 1-2% of the total cells in 90% of the tumors whereas in
10% of the tumors CD133 was highly expressed (range 15-40%). CD133 expression was confirmed by
immunohistochemistry (IHC) on tumor sections. CD133 positive and negative cells were sorted by FACS
from primary and xenografts tumors and injected subcutaneously in immunocompromised mice.
Preliminary evidences suggest that in most cases only CD133-enriched populations were able to
generate tumors compared to
CD133 negative. IHC analysis demonstrated that CD133 positive derived tumors recapitulated the
morphologic and phenotypic heterogeneity of the primary tumors Conclusions. These observations
indicate the presence in NSCLC of CD133 positive cells endowed with increased tumorigenic potential
which might represent a new target for treatment of lung cancer.
OP33
Differential Expression of Micro RNAs in Non-small Cell Lung Cancer
lSarah Runswick, 2 Elaine O'Neill, lSarah Fenton and 1AlexGraham
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Introduction: Small non-coding microRNAs (miRNAs) are functionally important in cancer development
and progression. Many miRNAs are differentially expressed in Non-small Cell Lung Cancer (NSCLC) and
normal lung tissue. Recently, miRNA expression profiling has been shown to be a powerful tool in
classification or prognosis of lung cancer. This study investigates the differential expression of miRNAs
in NSCLC and normal lung.
Objective/Purpose: Identify previously unreported miRNAs that are differentially expressed in NSCLC
and normal lung tissue by real time RT-PCR
Method: 16 matched pairs of NSCLC tumour (8 adenocarcinoma, 7 squamous cell carcinoma and 1
large cell carcinoma) and normal lung tissues were used for miRNA gene expression profiling by real
time RT-PCR of a panel of
157 miRNA assays (Early Access Panel, Applied Biosystems). Normalisation was performed using
GeNorm analysesand differential gene expression determined by the comparative delta Ct method.
Results and Conclusion: 39 differentially expressed miRNAs (p < 0.05, student's paired t-test) between
NSCLC and normal lung tissue were identified. Of these, 9 have previously been reported in the
literature to be differentially expressed and have known important function in lung cancer. 6/9 miRNAs
showed the same direction of regulation, whereas 3/9 did not concur with previous reports and miRNAs
were down-regulated rather than upregulated. MicroRNAs let-7a and mir-155, known prognostic
markers for NSCLC, were differentially expressed in squamous cell carcinoma (let-7a down-regulated
and mir-155 upregulated). In this study, 30 previously unreported significantly differentially expressed
miRNAs in NSCLC versus normal lung tissue were identified.
OP34
E17K mutation in AK.Tl gene in lung epidermoid carcinoma
Donatella Malanga1,2, Carmela De Marco1,2, Nicla De Rosa3, Gaetano Rocco4, Giuseppe Pirozzi4,
Giuseppe Viglietto1,2
1 Dipartimento di Medicina Sperimentale e Clinica "G Salvatore", Universita Magna Graecia, Campus
Universitario Germaneto, 88100, Catanzaro, Italy,
2 BIOGEM-Istituto di Ricerche Genetiche"G Salvatore", 83031, Ariano Irpino (AV), Italy
3 Azienda Ospedaliera Monaldi, 80131, Napoli, Italy
4 Istituto Nazionale dei Tumori "G Pascale, 80131, Napoli, Italy
Dysregulation of PI3K pathway plays a role in the development of lung cancer as PTEN loss or AKT
activation represents an unfavourable prognostic indicator for lung cancer patients. We investigated the
gene encoding AKT1 in NSCLC, through direct sequencing, in 105 resected, clinically annotated non-
small cell lung cancer specimens. We detected a G->A transition at nucleotide 49 (that results in E->K
substitution at residue 17) in two squamous cell carcinoma (2/36) but not in adenocarcinoma (0/53).
The activity of endogenous kinase carrying the E17K mutation immunoprecipitated from tumour tissue
was significantly higher compared with the wild-type kinase immunoprecipitated from adjacent normal
tissue as determined both by in vitro kinase assay using a consensus peptide as substrate and by in
vivo analysis of the phosphorylation status of AKT1 itself (pT308, pS473) or of known downstream
substrates such as GSK3 (pS9/S22) and p27 (T198). Immunostaining or immunoblot analysis indicated
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that enhanced membrane localization exhibited by endogenous E17K-AKT1 may account for increased
activity of mutant AKT1 in comparison with the wild-type protein from normal tissue. Subsequently, we
investigated the effects exerted by E17K-AKT1 in a cellular model of lung carcinoma. We found that
cells transfected by E17K-AKT1 are more resistant to drug-induced apoptosls in vitro and are more
tumourigenic in vivo. In conclusion, our data provide evidence that mutant E17K-AKT1 contribute to the
development of a subset of squamous lung carcinomas (5.5%).
OP35
Ubiquitin pool alterations in lung cancer
Josee Coulombe, Mei Zhang, Matthew Tang, and Douglas A Gray
Introduction: Ubiquitin is a small protein that when covalently attached to substrates serves as a
molecular 'tag' directing substrates into specific pathways or fates. We have previously shown that
when conjugated to PCNA, ubiquitin functions in a molecular switch that determines whether high or
low fidelity repair systems are utilized at the sites of DNA damage in lung cancer cells. It is likely that
such ubiquitin-based systems are sensitive to the availability of free ubiquitin. We hypothesize that
ectopic expression of UCHLl (previously shown to correlate with poor prognosis) is responsible for
elevated ubiquitin levels in certain lung cancers, thereby providing a growth advantage to lung cancer
cells.
Objective: To determine if ubiquitin levels are variable in lung cancers, and if so to determine the
mechanistic basis for this variability.
Method: Levels of ubiquitin and UCHLl were examined in tissue microarrays by immunohistochemistry.
The relationship of ubiquitin and UCHLl was explored through genetic manipulations in cell culture and
mouse models.
Results and conclusion: Ubiquitin levels are strongly influenced by the presence or absence of UCHLl.
The abundance of ubiquitin in normal lung tissues was fairly constant but ubiquitin and UCHLl levels
were highly variable in a mixed collection of lung cancers. Although the analysis is ongoing, there are
indications that levels of ubiquitin and UCHLl may be correlated in lung cancers. By targeting UCHLl it
may be possible to negate any advantage conferred on lung cancer cells through ectopic expression of
this enzyme.
OP36
Legal damages for preclinical commitment to cancer
Bernard W. Stewart Cancer Control Program, South EastSydney& IIIawarra
Public Health Unit and Faculty of Medicine, University of New South Wales, Sydney2031 Australia
Litigation predicated on the attributability of individual cancer to tobacco smoke has rarely been
successful (Stewart BW MedJAust 176:113-116,2002). The lack of success is ostensibly incongruous
when compared to the consideration that 75-80% of lung cancer is caused by smoking. The paradox is
an outcome from poor survival of lung cancer patients - and hence limited time being available for legal
proceedings - together with the challenge of establishing causation in relation to individuals rather than
populations. Neither limitation is relevant if the minority of individual smokers destined to develop lung
cancer could be identified; the focus of data evaluation undertaken in this study. Progress toward
establishing individual suscetibility may be considered with reference to lesions detected by computed
tomography or fluorescence bronchoscopy. For these procedures, limitations are sufficent to preclude
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population-based screeening at present. Molecular epidemiology provides some basis for susceptibility
indicated by P-450 and related drug-metabolizing enzymes and DNA repair processes, but data refer to
populations rather than the risk status of individuals. Expression profiling of tobacco-induced bronchial
dysplasia and tobacco-attributable genetic change, including mutation signatures in TP35 or RAS and
patterns of hypomethylation, may offer a stonger basis for identifying individuals whom are going to
develop lung cancer in advance of any clinical diagnosis. Currently, however, such inferences are
perceived as establishing biomarkers or individuals likely to benefit from chemoprevention. Accordingly,
the prospects for establishing, at law, the certainty of tobacco-induced cancer development in an
individual are remote at present. The goal remains a reasonable prospect for the future.
OP37
Peripheral blood SCG3 mRNA: a prognostic biomarker in SClC
Adrian C. Moss1,2,3, Gregory M. Jacobson1, Lauren E. Walker1, Neil W. Blake2, Ernie Marshall3, Judy
M. Coulson1
1 University of Liverpool, School of Biomedical Sciences, Liverpool, UK; 2 University of Liverpool,
Division of Medical Microbiology, Liverpool, UK; 3 Clatterbridge Centre for Oncology NHS Trust, Wirral,
UK.
Introduction: The REST/NRSF transcriptional repressor is inactivated in small cell lung cancer (SCLC)
facilitating neuroendocrine gene expression.
Specific markers of circulating tumour cells (CTC) may be informative in managing lung cancer.
Objectives: To evaluate the REST-regulated transcripts STMN2, CHGA, CHGB, SCG3, VGF, and PCSK1
as potential CTC biomarkers in SCLC. Methods: Transcripts were evaluated across lung cancer and
normal cells. Candidate biomarkers were assessed by RT-PCR and hybridization of RNA extracted from
peripheral blood of 113 lung cancer patients at clinical presentation and from 27 cancer free individuals
(CFI).
Results and Conclusion: STMN2 mRNA was detected in 48% of SCLC patients, 45% of non-SCLC
(NSCLC) patients and 94% of CFI. Thus it may be expressed by a specific lymphocyte population,
which intriguingly predicted for better prognosis in NSCLC (P=O.031). Expression profiling showed
multiple chromogranin transcripts were more readily inducible than STMN2 on conditional REST
depletion, notably SCG3 mRNA was highly elevated. SCG3 was also over-expressed by 12,OOO-fold in
neuroendocrine lung cancer, suggesting it is respectively more tumor-specific and sensitive than STMN2
or other chromogranins. 36% of SCLC and 14% of NSCLC patients scored positively for normalized
SCG3 transcript, which correlated with worse survival amongst SCLC patients with limited disease
(P=O.022). Importantly, SCG3 was also predictive of resistance to chemotherapy with
platinum/etoposide in SCLC (P=O.020). In NSCLC, unlike STMN2, SCG3 was associated with worse
survival (P=O.018). Thus SCG3, a component of the REST-dependent neurosecretory transcriptional
profile, provides a sensitive prognostic and predictive biomarker for non-invasive monitoring of
neuroendocrine lung cancers.
OP38
MCl-i/Ai Axis Addiction in Cisplatin Resistant Non-Small Cell lung Cancer Underlies
Sensitivity to the NOXA Mimetic Obatoclax
Nyree Crawford, Alex D. Chacko, Patrick G. Johnston, Dean A. Fennell
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Background and objectives: Resistance to apoptosis is a hallmark of cancer and contributes significantly
to the failure of cytotoxic therapy, particularly in relapsed non-small cell lung cancer (NSCLC) where
response to therapy is < 10%. Mitochondria are master regulators of the apoptosis pathway,
integrating multiple death signals that arise following cell damage, through activation of BAX/BAK.
Underststanding how this integrating function is modified in drug resistant NSCLC will be critical for
improving the effectiveness of therapy.
Methods and Results: Cisplatin-resistant NSCLC (cisRH460) were selected with log-fold reduced
sensitivity to parental cells (parRH460). CisRH460 exhibited cisplatin induced GO/G1 arrest, compared
with apoptosis induction in parH460. CisRH460 retained mitochondrial BAX/BAK suggesting intrinsic
pathway integrity. Accordingly, exogenous activating BH3 domains of BID or BIM induced BAX/ BAK
activation and mitochondrial outer membrane permeabilization with equal potency in
cisRH460/parH460. In isolated mitochondria, BID-BH3 induced BAX/BAK dependent depolarization, and
cytochrome C release independent of cristae remodelling, with generation of H202, cardiolipin
peroxidation, and damaged ultrastructure. CisRH460/parH460 were equally sensitive to the MCL-1/A1
antagonist NOXA-BH3, causing activation of BAX/BAK/caspase 9. Accordingly, the novel NOXA-BH3
mimetic obatoclax was equipotent in inhibiting ATP synthesis in both CisRH460 and parH460.
Conclusions: In summary, absent mitochondrial death signals underlie cisplatin resistance but can be
restored by a BH3- mimetic, opening the way to rational therapy of drug resistant NSCLC.
OP39
Early detection of lung cancer: is it possible a close link between Ct-scan screening and
molecular biomarkers in body fluids?
Carozzi, Francesca M, CSPO- Scientif Institute of Tuscany Region, Florence Paci Eugenio, Falini Patrizia,
Cristina Sani, Giulia Venturini, Laura Carrozzi, Florio Innocenti, Filomena Baliva, Andrea Lopes Pegna,
Giulia Picozzi and ltalung Working Group
Center for the Study and Cancer Prevention, Florence- Italy
Introduction: Since ideal biomarkers should be detectable in a biological fluid that can be obtained
noninvasively, many studies have focused on the detection of genetic abnormalities in exfoliated cells
from sputum as well as in the circulating DNAfound in plasma.
Objective: The main objectives of this study are: a) to detect cancer cells in sputum/plasma samples by
assessing their genomic damage, b) to study the association between biomarkers and malignant
modules, c) to identify markers that carry damage indicative of carcinogenic processes.
The final goal of our study was to evaluate the possible diagnostic value of molecular profile genes in
spontaneous sputum/blood sample, as a complementary approach to spiral CT for early diagnosis of
lung cancer.
Methods: In 2003, a randomise prospective trial (Ita lung) of early lung cancer detection was launched
in Italy (Tuscany), using low-dose spiral CT in a cohort of 1,500 high-risk heavy smoker. All the
subjects are invited to give a blood and sputum samples.
Results and conclusion: 1,311/,1500 subjects accepted to participate in the biomarker study.
Concurrently, we conducted a case-control study that includes all patients with Ct-scan tumor detected
and 77 consecutive heavy smokers from the study participants, who had a sample of sputum available
and were cancer free. We investigated in plasma and sputum Ras mutations,
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P53 mutations, methylation RARb-2, p161NK4A and RASSF1A, LOH at 12 loci and Free Dna in plasma.
The preliminary results will be reported and discussed.
OP40
NOXA-MCL-l-BAK Axis mediates Apoptosis following 205 Proteasome Inhibition by
Bortezomib in Mesothelioma: Implications for Therapy
Alex Chacko1, Nyree Crawford 1, Dario Barbone2, Luciano Mutti3, Courtney Broaddus2, Giovanni
Gaudino4, Dean A. Fennell1
1 Queen's University Belfast, 2 Lung Biology Centre, UCSF, 3 Lab. di Oncologia Clinica, Borgosesia ,
ItaIY,4 University of Piemonte orientale "A.Avogadro", Italy
Background: Malignant Mesothelioma (MM) is an apoptosis resistant cancer.
20S-proteasome inhibition by Bortezomib (Bz) is an approved anti-cancer strategy under evaluation in
MM based on preclinical data (I), and modulates the BCL-2 family (2).
Methods/Results: We explored Bz pharmacodynamics in MM, to better understand potential
sensitivity/resistance mechanisms relevant to our Phase-II trial. Bz exhibited logfold difference in EC50
between REN and MMP cell lines.
BAK-RNAi confirmed its requirement for apoptosis, whereas BAX-RNAi did not protect. Bz caused
mitochondrial outer membrane permeabilization and depolarization. Mitochondria from Bz primed MM
cells were sensitized to exogenous BID-BH3 domain reflecting modulation of mitochondrial apoptosis
signalling. In MMPs, Bz downregulated mitochondrial BCL-2/Al. BIM was upregulated and translocated
to mitochondria binding MCL-1 and de-repressing BAK. In MMPs and spheroids, NOXA was not
upregulated post Bz. In contrast, REN cells upregulated NOXA, which translocated to mitochondria and
disrupted a high molecular weight MCL-1-BAK complex. NOXA RNAi protected against Bz and
exogenous NOXA -BH3 (or obatoclax) induced apoptosis.
Conclusion: NOXA facilitates Bz toxicity by modulating BCL-2 proteins. This model suggests that loss of
critical components of this pathway may underlie therapeutic Bz resistance in MM, but may be
overcome by inhibiting MCL-1/Al.
1. Sartore-Bianchi et al., Clin Cancer Res 13, 5942
2. Fennell et al, Oncogene 2008 (EPub ahead of Print).
OP41
Inhibition of non-neuronal alpha7-nicotinic receptor as anticancer treatment for NSCLC
Alessia Catassi1,2, Laura Paleari1, Fausto Sessa2, Denis Servent3, Guido Doria_Miglietta1, Emanuela
Ognio1, Michele Cilli1, Lorenzo Dominioni2, Massimo Paolucci4, Andrea Calcaterra4, Alfredo Cesari05,6,
Stefano Margaritora5, Pierluigi Granone5 and Patrizia Russol.
1. National Cancer Research Institute, Lung Cancer Unit (PR, AC, AG, LP, GD-M), Animal Facility Unit
(EO, MC) Genoa, Italy 2. University of Insubria, Pathology Unit (FS),Thoracic Surgery Unit (AC, LD),
Varese, Italy; 3. CEA, iBiTecS, Service d'Inqenierie Moleculaire des Proteines (SIMOPRO), Gif sur Yvette,
F-91191, France. 4. Gallarate Hospital, Radiology Unit, Gallarate (Varese), Italy 5. Catholic University,
Thoracic Surgery Unit; Rome, Italy 6. IRCCS "San Raffaele", Rome, Italy.
Nicotinic acetylcholine receptors (nAChR) are expressed on bronchial epithelial and NSCLC cells and are
involved in cell growth regulation.
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Nicotine (classical nAChR agonist) induced cell proliferation, whereas nAChR antagonists, d-
tubocurarine or alpha-Cobratoxin (alpha-CbT), induced cell death. In the present study we further
explored the anti-tumour potential mechanisms and activities of alpha-CbT. NOD/SCID mice were
grafted intraperitoneally or orthotopically and treated with alpha-CbT.
alpha-CbT treatment [0.04 ng/Kg or 0.12 ng/kg] induced a strong reduction in tumour size (1V90% ) in
comparison with mice treated with the vehicle alone. Tumour inhibition was related to severe induction
of apoptosis.
Moreover neo-angiogenesis was strongly inhibited (reduction of cells positive to VEGF and CD31).
Biochemical analyses of the cells, isolated by the primary lung tumour inalpha-CbT-treated mice,
showed apoptosis features characterized by: (a) inhibition of BAD phosphorylation at Ser1l2 and
Ser136, (b) BAD dissociation from 14-3-3, (c) BAD association with BCl-Xl and (d) cleavage of
caspase-9. Moreover these cells were unable to grow in soft-agar and develop tumour, when re-
injected into mice. The small interfering RNA-mediated silencing of the alpha7-nAChR gene confirmed
that alpha-CbT specifically inhibited the alpha7-nAChR-mediated survival pathway in A549 cells.
Furthermore the specificity of alpha-CbT is reinforced by the lack of effect of short chain toxin
(Erabutoxin-a).
Once more, the no effect of the low affinity R33E modified alpha-CbT strengthened the specificity of
this inhibition. Although alpha7-nAChR antagonists such as alpha-CbT are unlikely to be a primary
therapy, it may provide lead compounds for the design of clinically useful drugs.
OP42
Clinical development of MAGE-A3 cancer immunotherapeutic in NSCLC: from proof-of-
concept to Phase III trials
Paul Taylor1, Johan Vansteenkiste2, Marcin Zielinski3, Albert Linder4, Jubrail Dahabreh5, Emilio
Esteban6, Wojciech Malinowski7, Jacek Jassem8, Bernward Passlick9, Marta lopez BrealO, Channa
Debruyne11
1North West lung Centre, Wythenshawe hospital, Manchester, UK; 2Respiratory Oncology Unit, Univ
Hosp, leuven, Belgium; 3Szpital Chorob Pluc, Zakopane, Poland; 4lungenKlinik, Hemer, Germany;
5Medical Centre, Athens, Greece; 6Hospital Central de Asturias, Oviedo, Spain; 7Szpital Kopernika,
Tusznin, Poland; 8Klinika Onkologii Radiotherapii, Gdansk, Poland; 9University Klinik, Freiburg,
Germany; 10Hospital Marques de Valdecilla, Santander, Spain; llGlaxoSmithKline Biologicals,
Rixensart, Belgium.
Introduction: MAGE-A3 recombinant protein combined with GSK proprietary immunological Adjuvant
System AS02B as adjuvant treatment for completely resected stage IB or II MAGE-A3 (+) NSClC has
been evaluated in a Phase II study (249553/004/NCT00290355).
Methods: Patients were randomly assigned to postoperative MAGE-A3 or placebo (2: 1) with
immunizations q3wx5, followed by q3mx8. Primary endpoint was disease-free interval (DFI); other
endpoints were safety, disease-free survival (DFS), overall survival (OS), assessment of humoral and
cellular anti-MAGE-A3 immune response.
Results: 182 patients (122 MAGE-A3, 60 placebo) were randomized: Median age 63 (45-81); 87%
male; 67% stage IB; 65% squamous cell carcinoma. After a median follow-up of 44 months, 69
recurrences and 57 deaths were recorded. Group comparisons of DFI, DFS and OS gave a hazard ratio
(HR) of 0.75 (95%CI=0.46-1.23, p=0.127), 0.76 (95%CI=0.48-1.21) and 0.81 (95%CI=0.47-1.40) in
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favor of the MAGE-A3 group, respectively. Treatment was well tolerated. 8% of the patients showed a
baselineanti-MAGE-A3 antibody response.
Induction of anti-MAGE-A3 IgG antibody response was observed in >98% of the patients immunized
with MAGE-A3. a CD4 T-cell response to MAGE-A3 was observed in 15 out of 37 (41%) immunized
patients, and only in 2 out of 14 (14%) patients in the placebo group. No correlation of immune
response and clinical outcome was observed.
Conclusions: This 44 month follow-up analysis confirms the positive signal for activity and
immunogenicity of the MAGE-A3 treatment in adjuvant NSCLC. An efficacy Phase III study (MAGRIT) is
ongoing. With a target of about 2,270 patients, this randomized (2: 1), double-blind, and placebo-
controlled MAGRIT trial enrolls patients with stage IB, II or IlIA resected NSCLC. MAGE-A3 Cancer
Immunotherapeutic administration will be initiated in two groups of patients: adjuvant to curative
surgery for the population where adjuvant chemotherapy is not standard of care and a second group of
patients that receive curative surgery with adjuvant chemotherapy will receive the MAGE-A3 following
this standard of care treatment. The primary endpoint of the trial is DFS. Other endpoints are clinical
and biological indicators for safety and efficacy. In addition, translational research to examine the
existence of a gene expression profile will also be investigated.
OP43
Low-dose gem in long infusion and cisplatin for mesothelioma
Matjaz Zwitter, Viljem Kovac
Institute of Oncology, Ljubljana, Slovenia
Introduction: After favourable experience with gemcitabine in low dose (130-250 mg/m2) in 6-hours
infusion in combination with cisplatin for advanced non-small cell lung cancer (Zwitter et ai, Anticancer
Drugs 2005;16:1129), we here present results from a Phase II trial for patients with mesothelioma.
Patients & Methods: Eligible patients had biopsy-proven malignant mesothelioma, were in fair general
condition (WHO performance status 0-2), had normal hematopoietic, liver and renal function and gave
informed consent. Treatment: gemcitabine 250 mg/m2/6 hours on days 1 & 8; cisplatin
75 mg/m2 on day 2 of a 3-week cycle for 4 cycles, followed by 2 additional cycleswithout cisplatin.
Results: Between 2003 and 2007, 75 patients (60 male; age 33 to 82 years, median 61) were recruited
into the trial. Histologic type: epitheloid (54); sarcomatoid (4); mixed (14), not specified (3). Three
patients were in progression after previous chemotherapy; others were chemonaive. Median number of
treatment cycles: 6. Toxicity: 4 grade III leucopenia; no grade IV toxicity; grade II nausea/vomiting
were common but manageable; reversible alopecia in all patients who received more than 2 cycles.
Tumor response: 3 CR; 37 PR (response rate 53%), . Additional 11 patients had minimal response with
symptomatic improvement. Median time to progression was 7.9 months, and median survival was 16.5
months. Factors which adversely affected survival were performance status 2 (median survival 9.8
months) and sarcomatoid or mixed histologic type (median survival 11.7 months).
Conclusion: Due to acceptable toxicity, remarkable activity and reasonable cost, this treatment should
be further explored.
OP44
Arsenic trioxide is highly cytotoxic to SCLC cells
Helen M. Petterssonl, Alexander Pietrasl, Matilda Munksgaard Perssonl, Jenny Karlssonl, Leif
Johansson2, Maria C. Shoshan3 and Sven P§hlmanl
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University, University Hospital MAS, Malmo, Sweden; 3 Department of Oncology and Pathology, Cancer
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Background: Small cell lung carcinoma (SCLC) is an extremely aggressive form of cancer and the
current treatments are insufficient. SCLC cells have neuroendocrine characteristics and show
phenotypical similarities to the childhood tumor neuroblastoma.
Purpose: On the basis of our previous studies showing that multidrug-resistant neuroblastoma cells are
highly sensitive to arsenic trioxide (As203) in vitro and in vivo, we studied the cytotoxic effect of As203
on SCLC cells.
Method: We investigated the in vitro and in vivo efficacy of As203 in killing SCLC cells using cell viability
assays and a nude mice-xenograft tumor model.
Western blot and flow cytometry analyses were used to characterize the mechanisms by which As203
induces SCLC cell death and the SCLC xenograft tumors were characterized immunohistochemically.
Results and conclusion: As203 induced pronounced cell death in SCLC cells at clinically relevant
concentrations, and also at hypoxia. SCLC cells were more sensitive than non-SCLC cells to As203. Cell
death was mainly due to necrosis, although apoptotic responses were also seen. A significant in vivo
effect of As203 on SCLC growth was observed and As203-treated tumors showed a decreased level of
vascularization as well as higher expression of neuroendocrine markers compared to control tumors. As
cultured SCLC cells grown at hypoxia, irrespective of whether they were treated with As203 or not,
showed an increase in neuroendocrine markers, anti-angiogenic induction of differentiation could be
part of the in vivo effect of As203 on SCLC growth. Our results suggest a potential clinical application
of As203 in SCLC therapy.
OP45
Quantification of neo-angiogenesis by micro-computed tomography in xenograft mouse
model of lung cancer
Rajkumar Savai1, Ralph T schermuly2, Alexander C Langheinrich3, Rio Dumitrascu2, Soni
S Pullamsetti2, Horst Traupe4, Wigbert S Rau3, Friedrich
Grimminger1,2 and GamalAndre Banatl
lDepartment of Hematology and Oncology, 2Internal Medicine, 3Radiology, 4Neuroradiology, University
of Giessen Lung Center (UGLC), Justus-liebig-University, Giessen, Germany.
Evaluation of lung tumor angiogenesis using imaging and immunohistochemical techniques has been
limited by difficulties in generating reproducible quantitative data. In this study, for analysing the
intrapulmonary tumors and their vascularisation we used high resolution micro computed tomography
(micro-CT). C57/BL6 mice were inoculated with Lewis lung carcinoma cell line via intratracheal injection
for lung tumor formation that was confirmed with flat panel volumetric computed tomography. Further
the lung vasculature was filled with radiopaque silicone rubber (Microfil). After polymerization of the
microfil, the lungs were harvested and investigated with micro-CT. For filling of the pulmonary vascular
tree, two different methods were applied
1) via jugular vein for in vivo application of microfil and 2) via pulmonary artery for ex vivo application
of microfil. Quantitative analysis of lung tumor microvessels with the analyze 7 software showed more
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vessels mainly the smaller vessels «0.02 mm2) were filled with in vivo (S.4%) compared to ex vivo
(2.1%). In addition, lung tumor bearing mice were treated site-specifically with anti-VEGF antibody
bevacizumab using osmotic minipump infusion for 14 days. Bevacizumab treatment significantly
reduced the lung tumor volume and the lung tumor vascularization compared to control mice as
assessed by micro-CT. Interestingly micovascularization mainly the smaller vessels «0.02 mm2) were
reduced following bevacizumab treatment. This observation with micro-CT was nicely correlated with
immunohistochemical measurement of microvessels. Therefore, micro-CT is a novel method
investigating tumor angiogenesis and might be considered as an additional and complementary tool to
quantitative histopathology.
OP46
EGFR and K-RAS Mutations on Fine Needle Aspirates of Lung Nodules.
Fassina A*, Gazziero A*, Aldighieri E?, Rossi G?
Departments *of Diagnostic Sciences and Special Therapy and ?of Clinical and Experimental Medicine?,
University of Padova
Introduction: Lung cancer (LC) is the most common cause of cancer death worldwide, and its prognosis
and therapy depend pathology findings.
Recently, somatic mutations of EGFR (exons 19 and 21) and K-RAS (exon 2) have been reported to
playa significant role in prognosis and in the choice of optimal therapy. We report the detection of
EGFR and K-RAS mutations by High Resolution Melting (HRM) analysis of DNA obtained by Fine Needle
Aspiration (FNA).
Methods: FNA material from 92 lung masses, (62 males, 68%, and 30 females, 32%; mean age
71.S6±9.24), was fixed in formalin or FineFIX©. DNA was extracted by phenol:chloroform and its
quality and quantity was checked on gel electrophoresis and spectrophotometer. EGFR and K-RAS
genes were analyzed using Gene Scanning Software for the HRM analysis.
Results: All 92 samples were wild type for EGFR gene and 8 cases (8.7%) had K-RAS mutation,
confirmed by sequencing .
Discussion: KRAS mutations occur in 10-30% of NSCLC cases and our results confirm these data, but
also for EGFR we can consider our findings in line with the literature (4%). Clinical trials with EGFR
Tyrosin Kinase inhibitors in the treatment of NSCL require mutation analysis which must be provided
rapidly and efficiently. HRM analysis is rapid, inexpensive and reliable and may provide a rapid
screening procedure. Cytology appears superior to biopsy for its low cost, minimal patient distress and
optimal DNA quality and quantity, particularly when the formalin-free FineFix© is used.
OP47
Analytical Evaluation of the ARCHITECT@ ProGRP Assay*
Toru Yoshimura1, Kenju Fujita1, Hideki Kinukawa1, Tohru Yamada1, Makoto Komori1, Eiji Kobayashi1,
Katsumichi Takeda1, Lori Sokoll2, Debra Elliott2, Daniel Chan2, Cornelia Scheuer3, Karin Hofmann3,
Petra Stieber3, Yousuke Sakurai4, Masayuki Iizuka4, Haruhisa Saegusa4, Sabrina ChanS, Barry DowellS
1 Abbott Japan, Matsudo, Japan; 2 The Johns Hopkins Hospital, Dept of Pathology, Baltimore, United
States; 3 University of Munich, Institute of Clinical Chemistry, Munich, Germany; 4 Denka Seiken,
Gosen, Japan; SAbbott Laboratories, Lake County, United States
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Introduction/Objectives: Pro-gastrin releasing peptide (ProGRP) levels in blood play an important role in
the diagnosis and treatment of small cell lung cancer (SCLC) patients. The automated quantitative
ARCHITECT@ ProGRP assay is being developed to aid in the differential diagnosis and in the
management of SCLC. The purpose of this study was to evaluate the analytical performance of this
chemiluminescent microparticle immunoassay (CMIA) with multiple-sites.
Methods: ARCHITECT@ ProGRP measures ProGRP by a two-step sandwich using monoclonal anti-
ProGRP antibodies coated on paramagnetic microparticles and labeled with acridinium. Analytical
performance of the assay was evaluated at 4 sites of (1) Abbott Japan, (2) The Johns Hopkins Hospital,
(3) University of Munich, and (4) Denka Seiken.
Results: A CLSI 20-day precision study was performed. The total precision CV% for 9 analyte levels was
between 2.9-5.7. The minimum limit of detection (analytical sensitivity) of the assay was between 0.20-
0.88 pq/rnl, (average 0.39 pq/rnl.). The limit of quantitation (20% CV)(functional
sensitivity) was between 0.66-1.73 pg/mL (average 1.13 pg/mL). The assay was linear up to 50000
pq/rnl, with a 1:10 autodilution protocol. The calibration curve was stable for 30 days. The comparison
with Fujirebio microtiter plate EIA ProGRP assay gave a slope of 0.93 and a correlation coefficient (r) of
0.99.
Conclusions: These preliminary results demonstrated the ARCHITECT@ ProGRP assay has excellent
analytical and functional sensitivity, precision, and correlation to a reference method. This assay
provides a convenient automated method for ProGRP measurement in serum and plasma in hospitals
and clinical laboratories.
OP48
MonoTotal vs, other cytokeratin markers in NSCLC
Authors : Jarmil Safranek, MOl, Vladislav Treska prof, PhD1 Ondrej Topolcan, prof, MD, PhD2 and
Lubos Holubec MD, PhD2.
l.Department of Surgery, Charles University and Faculty Hospital, Pilsen, Czech Republic; 2.Second
Internal Clinic, Charles University and Faculty Hospital, Pilsen, Czech Republic.
Objective/Purpose: To evaluate the diagnostic importance of MonoTotal and to compare it with
cytokeratin tumor markers (TPA, TPS and CYFRA 21-1) conventionally used in patients with NSCLC.
Methods: 179 patients were included in the study and were divided into two groups: 1) control group
(54 healthy indiViduals). 2) 125 patients with NSCLC, stage I-III operated on from 2005-2007 (87 of
them with squamous cell carcinoma /NSCLC Sq/ and 38 with adenocarcinoma /NSCLC AI). Tumor
markers were assessed using immunoanalytical methods. Sensitivities were calculated at 95%
specificity.
Results: Median MonoTotal levels were significantly higher in patients with NSCLC (Sq) 187 IU/L p<
0.001; NSCLC (A): 109 IU/L P < 0.05 in comparison with the control group. 65 IU/L. MonoTotal had a
sensitivity of 79/52% (NSCLC Sq/NSCLC A) and AUC was 0.9193/0.6874; CYFRA 21-1 76/22 % and
AUC was 0.8860/0.6111; TPA 71/44% and AUC was 0.8137/0.6018; TPS 29/22% and AUC was
0.6764/0.4351.
Conclusions: MonoTotal has significantly higher values in sera (in comparison with other cytokeratins)
and it is more sensitive than other conventionally used cytokeratin tumor markers. This difference is
most significant in squamous cell carcinoma.
This study was sponsored by the grant project IGA MZCR 9343-3.
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Prognostic impact of C4.4A in non-small cell lung cancer
B Jacobsen 1, BG Skov 2, LV Hansen 1,4, H Pappot 1,3, M Ploug 1
l " International Lung Cancer Conference
1 Finsenlaboratoriet, Rigshospitalet afsnit 3735, K0benhavn N, Denmark; 2 Patologisk afdeling,
Gentofte Hospital, Hellerup, Denmark; 3 Onkologisk afdeling, Rigshospitalet, K0benhavn 0, Denmark; 4
Present address:
DrugMode Aps, Odense M, Denmark
Introduction: C4.4A is a structural homologue of the urokinase-type plasminogen activator receptor,
which is a well-consolidated prognostic marker in human cancer. Although the biological function of
C4.4A remains elusive, the protein has been implicated in cancer invasion and metastasis. Objective:
The purpose of this study was to explore the possible association between C4.4A expression and
prognosis in patients with non-small cell lung cancer (NSCLC).
Method: An immunohistochemical, retrospective study was performed on formalin-fixed, paraffin-
embedded specimens from 104 patients, including 56 squamous cell carcinomas (SCC), 40
adenocarcinomas (AC) and 8 large cell carcinomas (LCC). Staining frequency and intensity was scored
semiquantitatively and grouped into cancers with high and low expression of C4.4A. Kaplan-Meier
survival curves were generated to evaluate the significance of C4.4A expression in prognosis of NSCLC
patients. Results and conclusion: High levels of C4.4A were found in 77% of SCC, 24% of AC and 13%
of LCC, thus correlating C4.4A expression to histological type of NSCLC. Survival data displayed a
correlation between high C4.4A expression and overall mortality in NSCLC patients (P = 0.012).
Intriguingly, the subgroup of patients having high C4.4A expression combined with a histological
classification as adenocarcinoma had a particularly poor survival (P < 0.0001), all patients dying within
2 years. This is the first demonstration of a very strong prognostic significance of C4.4A in NSCLC, with
a predominant impact on patients with AC. Preliminary data furthermore show that C4.4A might be a
marker of premalignant lesions of NSCLC.
OPSO
Discriminatory gene set for adenocarcinoma
Kristjan Valk
Tartu University Estonia
Introduction: Despite of lung cancer histological subgroup diagnostics, the clinical course of the same
stage patients is quite different. This fact suggests that histological form of cancer is not sufficient
predictor of clinical course of the disease.
Objectives: The aim of the current study was to identify the gene set that can discriminate the different
NSCLC subtypes.
Method: The cancer (120) and control samples of the current study originate from Tartu University
Hospital and are collected from 28.11.2002 to 31.12.2006. Tissue samples were snap frozen in liquid
nitrogen during the operation and processed in RNAlater ICE (Ambion) to eliminate RNA any
degradation. RNA was extracted using RiboPure Kit (Ambion) which was followed by RNA quantization
(Nanodrop) and quality control on Agilent Bioanalyzer Lab-on-a-Chip technology. RIN value cut-off was
set to 7. In the current study we have used IIIumina whole genome gene expression arrays of 47 000
features to monitor molecular patterns of different NSCLC samples.
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Results: We were able to discriminate different NSCLC types and identify characteristic genes involved
to the disease. As a result of the cluster analysis we identified genes that differentiated
adenocarcinoma and epidermoid cancer. Among these genes there were well-known cancer associated
genes like MMP15, MRP3, MMP17, MUC3B, TMEM92, FOLR1, PLA2G10, MUC1, RAGE and CD55.
OP51
Clinical Evaluation of the ARCHITECT® ProGRP assay*
Petra Stieber1, Rafael Molina2, Barry Dowell3, Robert Doss3, Toru Yoshimura4, Florian Blankenburg1,
Karin Hofmann1, Cornelia Scheuer1, Anne Htigg1, Rudolf Hatz5
1 Institute of Clinical Chemistry, University of Munich, Munich, Germany;
2 Laboratory of Biochemistry, Hospital Clinic, Medical School, Barcelona, Spain; 3 Abbott Laboratories,
Lake County, United States; 4 Abbott Japan, Matsudo, Japan; 5 Surgical Department, University of
Munich, Munich, Germany;
Introduction/Objective: ProGRP (Pro Gastrin Releasing Peptide) is known to be a biomarker with high
diagnostic capacity for small cell lung cancer (SCLC). Recently the first automated assay for the
determination of ProGRP became available (ARCHITECT®, Abbott Diagnostics). We evaluated the
clinical capacity of this new assay as compared to an established ELISA (ALSI, Japan).
Methods: We measured ProGRP with both assays in all samples under the same conditions. We
investigated retrospectively the sera (stored at -80°C) of 466 patients with histologically proven lung
carcinomas (123 SCLC, 343 non small cell lung cancer (NSCLC)). Sera of 183 patients with benign lung
diseasesand sera of 100 normals served as reference groups.
Results and Conclusion: For Architect® ProGRP median of normals was 21.7 pq/rnl (ALSI 20.9 ), 95th
percentile 37.7 pq/rnl (32.9). The median of benign lung diseases was 18.8 pq/rnl (16), 95th percentile
48 pq/rnl (42.9). The medians of squamous cell, adeno- and large cell carcinomas were 15.2, 15.7, 16.2
pq/rnl (12.8, 13.5, 14.8), 95th percentile 36.7, 40.4, 50.2 pq/rnl (31.4, 40.3, 50.2), highest value in
NSCLC 77.4 pq/rnl (74.3). In SCLC the median was 247 pq/rnl (249), 95th percentile 11130 pg/ml
(11476), highest value 250390 pq/rnl (253600). At 95% specificity for benign lung diseases Architect
ProGRP reached a sensitivity of 70% for SCLC (AUC 86%) (ALSI 72% (AUC 86%)). At 100% specificity
63% SCLC patients were true positive.
In summary the ARCHITECT® ProGRP assay represents an effective diagnostic tool for the detection of
SCLC.
OP52
Systematic review of brief smoking cessation intervention
Aveyard P, ParsonsA, Begh R
Department of Primary Care & General Practice, University of Birmingham, Birmingham B15 2TT
Introduction: The US national smoking cessation guidelines recommend the 5As: ask (about smoking
status), advise (a smoker to stop), assess (readiness to stop), assist (with medication), and arrange
(follow up). We reviewed the brief interventions in the Cochrane reviews of brief advice to stop
smoking and the nicotine replacement therapy (NRT) reviews to examine the evidence for the content
of the optimum intervention in smokers unselected by intention to stop smoking. Brief advice to stop is
said to work by increasing the number of quit attempts and NRT by increasing the likelihood of a quit
attempt being successful.
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Method: Systematic review examining the content of the interventions in the existing trials.
Results and conclusion: Asking was mostly done by researchers not the doctors in the studies.
Fourteen of 16 brief intervention studies tested advice to stop and most other elements of the 5As were
not incorporated. Two incorporated assessment and six studies included no assist intervention and
seven that handed over a leaflet, an intervention known to be almost ineffective. The overall rate ratio
(RR) for long-term cessation was 1.66 (1.42-1.94), but the two assist orientated interventions showed
evidence they were more effective 3.39 (1.77-6.49), with evidence that advise+assist was more
effective than advise only 2.47 (0.90-6.76). 42% of smokers used NRT, which worked to increase the
number of quit attempts, not only increase their success. Contrary to belief, advice to stop increased
quit success.
Based on these data, we propose a new briefer and evidence-based alternative to the 5As.
OP53
Smoking in Movies and Youth Tobacco Use Prevention
StaceyJ. Anderson
UKCTCS, University of Nottingham
Introduction: Ten years of evidence has been accumulating across four continents demonstrating that
smoking in movies has a significant impact on youth smoking uptake. This evidence base, and
significance of potential action to impact on the cinema as a recruitment system for the tobacco
industry, warrants further consideration.
Objective/Purpose: To assess the prevalence of smoking in movies shown on UK screens and estimate
the number of underaged smokers whose initiation can be attributed to smoking in movies.
Method: Analysis of 674 top-grossing movies shown in the UK between 2001 and 2006. Tobacco
occurrences are tallied and number of tickets sold for each movie are estimated (total gross / average
ticket price). Total number of tobacco impressions (tobacco occurrences X tickets sold) delivered to UK
cinema audiences are obtained. The contribution to percentage of the total tobacco impressions
delivered are calculated for each movie corporation as a means of identifying which corporations are
most responsible. Ratings for movies with and without smoking are noted and amount of tobacco
impressions delivered to audiences by youth-rated films (15 and below) are tabulated. Applying a
validated attributable risk figure, the number of British youth currently smoking that can be attributed
to their exposure to smoking in movies is estimated.
Results and Conclusion: It is anticipated that a substantial number of youth-rated films screened in the
UK contain smoking. Assigning an adult rating for smoking in movies could protect significant numbers
of British youth and prevent them from taking up smoking.
OP54
A systematic review to assess the effect of smoking on prognosis in lung cancer.
Amanda Parsons, Rachna Begh, Amanda Daley, Paul Aveyard
University of Birmingham, Department of Primary Care and General Practice, Birmingham, UK
Introduction: People diagnosed with lung cancer who smoke need to know whether it would make a
difference if they stopped. There are no randomised trials that have addressed this question and no
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NHS services we know that provide state of the art smoking cessation treatment to lung cancer
patients.
Purpose: To systematically review the evidence that smoking effects all cause mortality, disease specific
mortality and the development of a second primary/recurrence in lung cancer.
Methods: We searched bibliographic databases and reference lists to identify relevant studies. Two
people assessed the studies for inclusion against pre-set criteria and extracted data on population,
exposure and outcomes. We assessed the quality of the studies and strenght of the evidence. The
main outcome measure was survival to one of the endpoints in the research question, expressed as a
hazard ratio. Where confidence intervals for the estimate had not been reported, we calculated them
indirectly from other data presented or contacted the authors. We will conduct meta-analyses using
the random effects inverse variance method and test for statistical heterogeneity using 12 test.
Results and conclusion: 4822 OPs were identified of which 89 were relevant. Comparisons will be made
based on the patient, exposure and outcome characteristics and will be available by the time of the
conference. Comparision of survival outcomes between continuing smokers and smokers who gave up
at the time of diagnosis provide the strongest evidence, but many studies contrast smoking status at
diagnosis (ex, current, or never smokers) or used lifetime smoking as the exposure variable. This will
allow us to assess if smoking cessation at diagnosis provides enough time to impact survival.
OP55
Epidemiology of Smoking among 15 to 64 Years Old Iranians
Mehrabi S 1, Delavari A 2, Moradi Gh 3, Esmailnasab N 4, Pooladi A 5, Alikhani S 6, Alaeddini F7 1Shiraz
University of Medical Sciences, Department of Internal Medicine, Shiraz, Iran;2Tehran
University of Medical Sciences, Endocrine Research Center, Tehran, Iran;3Kurdistan University of
Medical Sciences, Research Chancellor Office, Sanandaj, Iran;4Kurdistan University of Medical Sciences,
Department of Community Medicine, Sanandaj, Iran;5Kurdistan University of Medical Sciences,
Education Development Center, Sanandaj, Iran;6Ministry of Health and Medical Education, Center for
Disease Control, Tehran, Iran;7National Research Center for Medical Sciences of Iran, Tehran, Iran
Introduction: Tobacco smoking is known to cause a huge burden of disease throughout the world:
smoking is responsible for 4 million deaths per year.
Objective: This study is performed in order to fill the existing gaps in information regarding current
trends for lifestyle and tobacco-related disease in Iran.
Method: This was a cross-sectional study performed with the help of a questionnaire and using a multi-
stage cluster sampling method. The final sample size, after the screening of the data, was 84706 out of
89457 records.
Results and Conclusion: From a total of 84706 people in this study, 49.7% were men, 52% were
uneducated and 64.8% cane from urban areas; 79.9% did not smoke, 15.3% smoked actively, 2.1%
were non-active smokers and 2.7% were ex-smokers. The prevalence of smoking was higher in people
aged 35 to 64 years (P<O.OOl). QUitting rates increased with age, especially in women (P<O.OOl).
Smoking was more prevalent in men (P<O.OOl) and in rural areas (P<O.OOl). The average number of
cigarettes smoked per day was 14.69. Smoking prevalence was lower among adults with higher levels
of education compared to those with lower education levels (P<O.OOl). This nationwide survey provides
a baseline for future longitudinal studies of smoking in Iran. There is a need for effective smoking
prevention and cessation programs with a focus on the young population.
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Making support to quit smoking more accessible
Christine Owens MHSc BA (Hons) Director of Tobacco Control The Roy Castle Lung Cancer Foundation,
Liverpool, UK
Roy Castle Fag Ends have been providing community based stop smoking support on Merseyside since
1994. The experience of this 'grass roots' approach to the provision of stop smoking support has
allowed the development of a model which is recognised as a successful approach to stop smoking
provision, particularly within hard to reach communities with high smoking prevalence.
The model works by removing barriers and providing instant access to weekly sessions which run
continuously, allowing new clients to join at any time by simply walking into a group, which is the main
mode of access to the service, demonstrating the popularity of the approach. Essential principles
include:
No waiting list
No appointment
No requirement to be referred by a third party, although referral systems are in place
Referrals can be made to the service in a variety of ways:
Fax referral from GPs and other health professionals
Self referral via the freephone telephone helpline
Referral from the NHS National helpline
People can refer themselves by walking into their local group
In Liverpool and Knowsley, where Fag Ends run the NHS stop smoking services, the results for the first
two quarters of 2007/08 are as follows:
Liverpool Population 447,500
Setting a quit date - 6844
4 week quitters - 3013
QUit rate - 44%
4 week quitters Per 100,000 population - 841
Knowsley Population 151,300
Setting a quit date - 2899
4 week quitters - 1413
Quit rate - 49%
4 week quitters Per 100,000 population 1179
OP57
Infiltration of tumour islets by Ml macrophages is associated with extended survival in
non-small cell lung cancer
CM Ohri, A Shikotra, RH Green, DA Waller & P Bradding
Institute for Lung Health, Departments of Infection, Immunity and Inflammation, University of
Leicester, and Respiratory Medicine and Thoracic Surgery, Glenfield Hospital, Leicester
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Introduction: There is a marked survival advantage for patients with non-small cell lung cancer (NSCLC)
expressing high numbers of macrophages in their tumour islets.
Purpose: This study investigated the immunological phenotype of macrophages in NSCLC tumour islets
and stroma.
Methods: Using immunohistochemistry, we identified CD68+ macrophages and markers of either a
cytotoxic M1 phenotype (HLA-DR, inducible nitric oxide synthase [iNOS], myeloid-related protein 8/14
dimerisation [MRP 8/14] and tumour necrosis factor-alpha [TNFa]), or a non-cytotoxic M2 phenotype
(CD163). These were analysed in the tumour islets and stroma of surgically resected tumours from 20
patients with extended survival (median 92.7 months) compared to 20 patients with poor survival
(median 7.7 months).
Results: The density of all macrophage markers was significantly increased in the islets of extended
survival patients compared to poor survival patients (p<0.001 for each marker). The density of M1
macrophages was increased in the tumour islets of extended survival patients compared to M2
macrophages (p=0.05). Numbers of M1 and M2 macrophages were similar in the tumour stroma of
both groups. The islet:stromal ratio of M2 macrophages was markedly reduced compared to M1
macrophages in extended survival patients (p<0.001). Increasing numbers of total islet macrophages
and each islet macrophage marker were associated with markedly improved survival.
Conclusion: Macrophages infiltrating the tumour islets in NSCLC are predominantly of the M1 phenotype
in patients with extended survival. This supports the view that the survival advantage conferred by islet
macrophage infiltration is related to their cytotoxic anti-tumour activity.
OP58
Expression of eIF4E in non-small cell lung cancer in response to IGF-l, An in vitro study
Farhad Mashayekhi, Zivar Salehi and Mohammad Naji
Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran
Introduction: Eukaryotic translation initiation factor eIF4E, which binds to the 5' cap structure of mRNA,
plays an important role in translation regulation and it has been suggested that it is implicated in
increased protein synthesis promoted by growth factors. The overexpression of eIF4E is involved in the
malignant progression of various human cancers. Growth factors have been implicated in cell
proliferation. There is abundant evidence that IGF-1 promotes protein synthesis, a requirement for
induction of cell growth and proliferation. The finding that growth factors promote protein synthesis has
led us to investigate the eIF4E expression in non-small cell lung cancer in vitro. We investigated IGF as
it is one of the most important growth factors and it is an important factor in cell proliferation.
Objectives: In this study the Expression of eIF4E in non-small cell lung cancer in response to IGF-1 has
been investigated in vitro.
Methods: eIF4E expression and 4EBP1 phosphorylation status in non-small cell lung cancer in response
to IGF-1 was studied using isoelectric focusing and western blot.
Results and Conclusion: Using anti-eIF4E antibody it was found that eIF4E level is increased in non-
small cell lung cancer in response to IGF-l. It was shown that 4EBP1 hypophosphorylated in response
to IGF-l. The present study shows that eIF4E is phosphorylated in the non-small cell lung cancer
treated with IGF-1 in vitro. It is concluded that the overexpression of eIF4E and hypophosphorylation of
4EBP1 may be involved in the pathophysiology of lung cancer.
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eIF4E expression and 4EBPl phosphorylation status in lung cancer
Zivar Salehi, Farhad Mashayekhi and Mohammad Naji
Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran
Introduction: Control of protein synthesis resides at the level of eIF-4F complex formation. The
eukaryotic initiation factor 4E (eIF4E) has been shown to playa key role in cell growth, and several
studies have documented an increased expression of elF4E in a number of solid tumors, including
breast, bladder, cervical, esophageal and head and neck cancers.
During translation initiation, the eIF4E-mRNA complex binds to elF4G and elF4A to form the active
elF4F complex. The active eIF4E-eIF4G complex allows binding of mRNA to the 43S preinitiation
complex and elongation proceeds.
Objectives: The aim of this study was to determine the level of expression of elF4E and elF4E-binding
protein 1 (4E-BP1) in lung cancer. Tumor and normal adjacent tissue samples (as controls) were
obtained from 45 patients with lung cancer.
Method: elF4E and 4E-BP1 levels were determined by using immunohistochemistry and Western blot
analysis. elF4E was purified by affinity chromatography using m7GTP-sepharose, and the levels of 4E-
BP1 bound to elF4E were determined.
Results and Conclusion: In cancerous lung tissues, elF4E level was elevated by a mean of 3.2 ± 0.5-
fold, and 4E-BP1 was elevated by a mean of 5.3 ± O.7-fold when compared to normal adjacent tissues.
Both elF4E and 4E-BP1 expressions were higher in cancerous compared to noncancerous lung tissues.
A higher expression of elF4E was correlated with advanced stages.
The results from this study support the hypothesis that the overexpression of elF4E can be involved in
tumorigenesis and a possible role of 4E-BP1 as a prognostic factor in lung cancer.
OP60
Expression of Livin and Survivin in Lung Cancer
A Fassina1, A Gazziero1, D Zardo1, M Corradin1, D Boldrin2, A Rosato2
Department of Diagnostic Medical Sciences and Special Therapies, Section of Pathology 1, and
Department of Oncology and Surgical Sciences 2, University of Padua, Padova, Italy.
Introduction: Lung Cancer (LC) is the leading cause of cancer death worldwide. Clinical and pathological
characteristics cannot accurately predict patients outcome, and we are in need of molecular markers to
identify high-risk patients and targeted therapies. Human Inhibitors of Apoptosis Protein (lAP), such
Livin (L) and Survivin (S) have been found in NSCLC and SCLC cells, however their prognostic role are
still poorly defined.
Objective/Purpose: Investigation of Land S expression in LC with Real Time PCR and immuno-
histochemistry (IIC); and the association between patient clinical and pathological characteristics and
prognosis.
Methods: 59 cases of LC (31 NSCLC and 29 SCLC) were selected from the Archive of Pathology, Padova
University; 10 biopsies from lungs of normal individuals were used as control. All neoplastic and non-
neoplastic tissues were formalin fixed and paraffin embedded (PET). Two sections were used for IIC
and 2 10-micron thick sections for RNA extraction and cDNA preparation.
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Results and Conclusion: Land S mRNA expression was significantly higher in neoplastic than in non-
neoplastic lung tissues (p<O,OOl). S mRNA expression was significantly higher in SCLC than in NSCLC
(p<0,05). No correlation between Land S expression and clinical and pathological characteristics was
observed, nor with patient's survival.
Sand L can be satisfactorily investigated from PET by means of RT-PCR better than lIC; appear as
selectively expressed in LC; cannot be employed as markers for prognostic, but to ultimately supervise
targeted therapy.
OP61
Are CYFRA 21-1 and CEA prognostic factors in female stage I NSCLC patients?
Florian Blankenburgl, Rudolf Hatz2, Dorothea Nagell, Judith Reinmiedl3, Dietrich Seidell, Petra
Stieberl
!Institute of Clinical Chemistry, Klinikum der Unlversitat MOnchen -GroBhadern-, MarchioninistraBe 15,
81377 MOnchen, Germany
2 Surgical Department, Klinikum der Unlversltat MOnchen -GroBhadern-, Germany
3 Asklepios Lungenfachkliniken, Gauting, Germany
Introduction: It is known that female patients suffering from early stages of non-small cell lung cancer
(NSCLC) have a better survival than male patients.
Objective: For that reason it was our aim to evaluate the prognostic factors in stage I NSCLC female
patients.
Methods: We retrospectively examined 73 stage I NSCLC patients (28 pTl, 45 pT2; 47 Adeno-, 18
Squamous-Cell-, 8 Large-Cell-Carcinoma) treated between 1986 and 2004 in our institution by complete
resection (RO). We investigated prognostic impact on survival of preoperative levels of CEA (Abbott,
AxSym), CYFRA 21-1 (Roche, Elecsys), LDH, alcalic phosphatase, creatinine, CRP, Natrium, Kalium,
Glucose, CHE, GOT, yGT, Calcium, haemoglobin, erythroytes, leucozytes, thrombocytes on a continuous
logarithmic scale and in addition using cutpoints.
Results and Conclusion: The overall 3-/5-year survival was 77.4% and 69.3%. There were no
significant differences between pTl and pT2 patients, the histological subtypes and age. In univariate
analysis using logarithmic transformation of the data CYFRA 21-1 (p=0.0087), serum creatinine
(p=0.026) and calcium (p=0.034) were prognostic factors for a worse outcome, CEA was only
significant respecting a quite high cutpoint of 7.5 ng/ml (p=0.046).
Using logarithmic transformation in multivariate analysis only CYFRA 21-1 remained a prognostic factor,
whether CEA had additional prognostic impact depends on the cut points used for both markers.
In summary, elevated levels of CYFRA 21-1 and possibly CEA correspond with poorer outcome in early
stage of NSCLC in female patients.
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